```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 08   CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS  3  JAN 16   CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS  4  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS  5  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS  6  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS  7  JAN 22   CA/CAplus enhanced with patent applications from India
 NEWS  8  JAN 29   PHAR reloaded with new search and display fields
 NEWS  9  JAN 29   CAS Registry Number crossover limit increased to 300,000 in
                   multiple databases
 NEWS 10  FEB 15   PATDPASPC enhanced with Drug Approval numbers
 NEWS 11  FEB 15   RUSSIAPAT enhanced with pre-1994 records
 NEWS 12  FEB 23   KOREAPAT enhanced with IPC 8 features and functionality
 NEWS 13  FEB 26   MEDLINE reloaded with enhancements
 NEWS 14  FEB 26   EMBASE enhanced with Clinical Trial Number field
 NEWS 15  FEB 26   TOXCENTER enhanced with reloaded MEDLINE
 NEWS 16  FEB 26   IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 17  FEB 26   CAS Registry Number crossover limit increased from 10,000
                   to 300,000 in multiple databases
 NEWS 18  MAR 15   WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS 19  MAR 16   CASREACT coverage extended
 NEWS 20  MAR 20   MARPAT now updated daily
 NEWS 21  MAR 22   LWPI reloaded
 NEWS 22  MAR 30   RDISCLOSURE reloaded with enhancements
 NEWS 23  APR 02   JICST-EPLUS removed from database clusters and STN
 NEWS 24  APR 30   GENBANK reloaded and enhanced with Genome Project ID field
 NEWS 25  APR 30   CHEMCATS enhanced with 1.2 million new records
 NEWS 26  APR 30   CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 27  APR 30   INPADOC replaced by INPADOCDB on STN
 NEWS 28  MAY 01   New CAS web site launched
 NEWS 29  MAY 08   CA/CAplus Indian patent publication number format defined
 NEWS 30  MAY 14   RDISCLOSURE on STN Easy enhanced with new search and display
                   fields
 NEWS 31  MAY 21   BIOSIS reloaded and enhanced with archival data
 NEWS 32  MAY 21   TOXCENTER enhanced with BIOSIS reload
 NEWS 33  MAY 21   CA/CAplus enhanced with additional kind codes for German
                   patents
 NEWS 34  MAY 22   CA/CAplus enhanced with IPC reclassification in Japanese
                   patents

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:50:04 ON 07 JUN 2007

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 17:50:40 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUN 2007 HIGHEST RN 936692-95-4
DICTIONARY FILE UPDATES: 6 JUN 2007 HIGHEST RN 936692-95-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> e d-threo-methylphenidate/cn
E1            1      D-THREO-L-TALO-UNDECONIC ACID, 6,10-ANHYDRO-2,3,4,5-TETRADEO
                     XY-2-(((1,1-DIMETHYLETHOXY)CARBONYL)AMINO)-7,8,9,11-TETRAKIS
                     -O-(PHENYLMETHYL)-/CN
E2            1      D-THREO-L-TALO-UNDECONIC ACID, 6,10-ANHYDRO-2,3,4,5-TETRADEO
                     XY-2-(((1,1-DIMETHYLETHOXY)CARBONYL)AMINO)-7,8,9,11-TETRAKIS
                     -O-(PHENYLMETHYL)-, METHYL ESTER/CN
E3            1 --> D-THREO-METHYLPHENIDATE/CN
E4            1      D-THREO-METHYLPHENIDATE HYDROCHLORIDE/CN
E5            1      D-THREO-MONAPTERIN/CN
E6            1      D-THREO-N-(2-HYDROXY-1-(HYDROXYMETHYL)-2-(4-NITROPHENYL)ETHY
                     L)ACETOACETAMIDE/CN
E7            1      D-THREO-N-(TRIFLUOROACETYL)-2-AMINO-1-(4-NITROPHENYL)-1,3-PR
                     OPANEDIOL/CN
E8            1      D-THREO-N-BENZOYL-1-P-NITROPHENYL-2-AMINO-1,3-PROPANEDIOL/CN
E9            1      D-THREO-N-DICHLOROACETYL-1-P-NITROPHENYL-2-AMINO-1,3-PROPANE
                     DIOL/CN
E10           1      D-THREO-N-HEXADECANNOYLSPHINGENINE/CN
E11           1      D-THREO-N-PHTHALOYL-3-(3,4-DIHYDROXYPHENYL)SERINE-QUININE SA
                     LT/CN
E12           1      D-THREO-NEOPTERIN/CN

=> s e3
L1            1 D-THREO-METHYLPHENIDATE/CN

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   40431-64-9  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   2-Piperidineacetic acid, α-phenyl-, methyl ester, (αR,2R)-
     (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   2-Piperidineacetic acid, α-phenyl-, methyl ester, [R-(R*,R*)]-
OTHER NAMES:
CN   (+)-threo-Methylphenidate
CN   d-threo-Methylphenidate
CN   Dexmethylphenidate
CN   Methyl D-phenidate
CN   threo-(+)-Methylphenidate
FS   STEREOSEARCH
MF   C14 H19 N O2
CI   COM
LC   STN Files:   ADISINSIGHT, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS,
       CASREACT, CBNB, CIN, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*,
```

PHAR, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

108 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
108 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file merck

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.35	7.56

FILE 'MRCK' ENTERED AT 17:51:16 ON 07 JUN 2007

FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: OCTOBER 2005

=> d his

(FILE 'HOME' ENTERED AT 17:50:04 ON 07 JUN 2007)

FILE 'REGISTRY' ENTERED AT 17:50:40 ON 07 JUN 2007
E D-THREO-METHYLPHENIDATE/CN
L1 1 S E3

FILE 'MRCK' ENTERED AT 17:51:16 ON 07 JUN 2007

=> s l1
L2 1 L1

=> d all

L2 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2007 Merck and Co., Inc., Whitehouse Station, New Jersey, USA. All rights reserved. on STN
MERCK Number (MNO): 6132
CAS Registry No. (RN): 113-45-1
MERCK Index Name (MIN): Methylphenidate
CA Index Name (CN): α-Phenyl-2-piperidineacetic acid methyl ester
Synonym(s) (CN): Methyl phenidylacetate; Methyl α-phenyl-α-(2-piperidyl)acetate; Methylphenidan
Molecular Form. (MF): C14 H19 N O2
Wgt Composition (COMP): C 72.07%, H 8.21%, N 6.00%, O 13.72%.
Molecular Weight (MW): 233.31
References (RE): Prepn: L. Panizzon, Helv. Chim. Acta 27, 1748 (1944); M. Hartmann, L. Panizzon, US 2507631 (1950 to Ciba). Sepn of isomers: R. Rometsch, US 2957880 (1960 to Ciba). Toxicity data: E. N. Greenblatt, A. C. Osterberg, J. Pharmacol. Exp. Ther. 131, 115 (1961). Comprehensive description: G. R. Padmanabhan, Anal. Profiles Drug Subs. 10, 473-497 (1981). Pharmacokinetics: N. R. Srinivas et al., Pharm. Res. 10, 14 (1993). Clinical efficacy in attention deficit-hyperactivity disorder (ADHD): W. E. Pelham, Jr. et al., J. Consult. Clin. Psychol. 61, 506 (1993); R. G. Klein, Encephale 19, 89 (1993).



Boiling Point (BP):

Value BP deg C	Pressure BP.P mm Hg
135 - 137	0.6

Other Properties (OCPP):
bp0.6mm 135-137° . Sol in alcohol, ethyl acetate, ether. Practically insol in water, petr ether.

== DERIVATIVE == (1): Hydrochloride
CAS Registry No. (RN.DRV): 298-59-9
Drug Code(s) (CN.DRV): Ciba 4311b
Trade Name(s) (CN.DRV): Centedrin (Gedeon Richter); Concerta (Alza); Equasym (UCB); Metadate (Medeva); Ritalin (Novartis)
Molecular Form. (MF.DRV): C14 H19 N O2 . Cl H
Wgt Composition (COMP.DRV): C 62.33%, H 7.47%, N 5.19%, O 11.86%, Cl 13.14%.
Molecular Weight (MW.DRV): 269.77



HCl

Melting Point (MP.DRV):

Deriv. Number	Derivative Type	Value MP.DRV deg C
1	Hydrochloride	224 - 226

Toxicity (TOX.DRV):
LD50 orally in mice: 190 mg/kg (Greenblatt, Osterberg).
Other Properties (OCPP.DRV):
Crystals, mp 224-226° . pKa 8.9. Sol in water, alc, chloroform. A 5% aq soln is neutral to litmus. LD50 orally in mice: 190 mg/kg (Greenblatt, Osterberg) .

== DERIVATIVE == (2): d-threo-Form
CAS Registry No. (RN.DRV): **40431-64-9**
CA Index Name (CN.DRV): (αR,2R)-α-Phenyl-2-piperidineacetic acid methyl ester
Synonym(s) (CN.DRV): Dexmethylphenidate
References (RE.DRV): Enantioselective synthesis: J. M. Axten et al., J. Am. Chem. Soc. 121, 6511 (1999).

Absolute stereochemistry. Rotation (+).



== DERIVATIVE == (3): d-threo-Form hydrochloride
CAS Registry No. (RN.DRV): 19262-68-1
Synonym(s) (CN.DRV): Dexmethylphenidate hydrochloride
Trade Name(s) (CN.DRV): Focalin (Novartis)
References (RE.DRV): Clinical trials in ADHD: L. E. Arnold et al., J. Child Adolesc. Psychopharmacol. 14, 542 (2004); R. Silva et al., ibid. 555.

Absolute stereochemistry. Rotation (+).



HCl

Other Properties (OCPP.DRV):
White to off-white powder. Freely sol in water, methanol; sol in alcohol; slightly sol in chloroform, acetone.

Notes (NTE):
Note: This is a controlled substance (stimulant): 21 CFR, 1308.12.
Therapeutic Codes (THER):
CNS stimulant.
Referenced Patent (RPN):
US2507631; US2957880

=> file medline
COST IN U.S. DOLLARS SINCE FILE ENTRY 3.64 TOTAL SESSION 11.20
FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 17:51:45 ON 07 JUN 2007

FILE LAST UPDATED: 6 Jun 2007 (20070606/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s monoamine transport? inhibit?
24166 MONOAMINE
341244 TRANSPORT?
1344272 INHIBIT?
L3 34 MONOAMINE TRANSPORT? INHIBIT?
(MONOAMINE(W)TRANSPORT?(W)INHIBIT?)

=> s parkinson?
L4 51353 PARKINSON?

=> s l1
L5 0 L1

=> s (d-threo-methylphenidate or dexmethylphenidate)

```
        632913 D
          1726 THREO
          4372 METHYLPHENIDATE
            26 D-THREO-METHYLPHENIDATE
                 (D(W)THREO(W)METHYLPHENIDATE)
            21 DEXMETHYLPHENIDATE
L6          46 (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)

=> s l3 or l6
L7          80 L3 OR L6

=> s l3 and l6
L8           0 L3 AND L6

=> s l3 and l4
L9           3 L3 AND L4

=> s l4 and l6
L10          5 L4 AND L6

=> s l4 and l7
L11          8 L4 AND L7

=> d l9 1-3

L9   ANSWER 1 OF 3     MEDLINE on STN
Full Text
AN   2006480446     MEDLINE
DN   PubMed ID: 16903863
TI   Partial depletion of dopamine in substantia nigra impairs motor
     performance without altering striatal dopamine neurotransmission.
AU   Andersson Daniel R; Nissbrandt Hans; Bergquist Filip
CS   Department of Pharmacology, Institute of Neuroscience and Physiology, The
     Sahlgrenska Academy at Goteborg University, Box 431, SE 405 30 Goteborg,
     Sweden.. daniel.andersson@pharm.gu.se
SO   The European journal of neuroscience, (2006 Jul) Vol. 24, No. 2, pp.
     617-24.
     Journal code: 8918110. ISSN: 0953-816X.
CY   France
DT   Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA   English
FS   Priority Journals
EM   200610
ED   Entered STN: 15 Aug 2006
     Last Updated on STN: 4 Oct 2006
     Entered Medline: 3 Oct 2006

L9   ANSWER 2 OF 3     MEDLINE on STN
Full Text
AN   2005114124     MEDLINE
DN   PubMed ID: 15707697
TI   Inhibition of vesicular monoamine transporter enhances vulnerability of
     dopaminergic cells: relevance to Parkinson's disease.
AU   Choi Hyun Jin; Lee So Yeon; Cho Yuri; Hwang Onyou
CS   Department of Biochemistry and Molecular Biology, University of Ulsan
     College of Medicine, 388-1 Pungnap-dong, Songpa-ku, Seoul 138-736, South
     Korea.
SO   Neurochemistry international, (2005 Mar) Vol. 46, No. 4, pp. 329-35.
     Electronic Publication: 2005-01-17.
     Journal code: 8006959. ISSN: 0197-0186.
CY   England: United Kingdom
DT   Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA   English
FS   Priority Journals
EM   200505
ED   Entered STN: 5 Mar 2005
     Last Updated on STN: 12 May 2005
     Entered Medline: 11 May 2005

L9   ANSWER 3 OF 3     MEDLINE on STN
```

Full Text
AN 89061774 MEDLINE
DN PubMed ID: 3264161
TI Characteristics of the transport of the quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules.
AU Darchen F; Scherman D; Desnos C; Henry J P
CS Institut de Biologie Physico-Chimique, C.N.R.S. UA 1112, Paris, France.
SO Biochemical pharmacology, (1988 Nov 15) Vol. 37, No. 22, pp. 4381-7. Journal code: 0101032. ISSN: 0006-2952.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 198812
ED Entered STN: 8 Mar 1990
Last Updated on STN: 8 Mar 1990
Entered Medline: 30 Dec 1988

=> d his

(FILE 'HOME' ENTERED AT 17:50:04 ON 07 JUN 2007)

FILE 'REGISTRY' ENTERED AT 17:50:40 ON 07 JUN 2007
E D-THREO-METHYLPHENIDATE/CN
L1 1 S E3

FILE 'MRCK' ENTERED AT 17:51:16 ON 07 JUN 2007
L2 1 S L1

FILE 'MEDLINE' ENTERED AT 17:51:45 ON 07 JUN 2007
L3 34 S MONOAMINE TRANSPORT? INHIBIT?
L4 51353 S PARKINSON?
L5 0 S L1
L6 46 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)
L7 80 S L3 OR L6
L8 0 S L3 AND L6
L9 3 S L3 AND L4
L10 5 S L4 AND L6
L11 8 S L4 AND L7

=> d l10 1-5

L10 ANSWER 1 OF 5 MEDLINE on STN
Full Text
AN 2006033499 MEDLINE
DN PubMed ID: 15959851
TI (11)C]**d-threo-methylphenidate** PET in patients with **Parkinson**'s disease and essential tremor.
AU Breit S; Reimold M; Reischl G; Klockgether T; Wullner U
CS Department of Neurology, University of Tubingen, Tubingen, Germany.. breit@uni-tuebingen.de
SO Journal of neural transmission (Vienna, Austria : 1996), (2006 Feb) Vol. 113, No. 2, pp. 187-93. Electronic Publication: 2005-06-15. Journal code: 9702341. ISSN: 0300-9564.
CY Austria
DT (CONTROLLED CLINICAL TRIAL) Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T) (CLINICAL TRIAL)
LA English
FS Priority Journals
EM 200608
ED Entered STN: 20 Jan 2006
Last Updated on STN: 17 Aug 2006
Entered Medline: 16 Aug 2006

L10 ANSWER 2 OF 5 MEDLINE on STN
Full Text
AN 2005628952 MEDLINE
DN PubMed ID: 16081470

TI PET in LRRK2 mutations: comparison to sporadic **Parkinson**'s disease and evidence for presymptomatic compensation.
AU Adams John R; van Netten Hinke; Schulzer Michael; Mak Edwin; Mckenzie Jessamyn; Strongosky Audrey; Sossi Vesna; Ruth Thomas J; Lee Chong S; Farrer Matthew; Gasser Thomas; Uitti Ryan J; Calne Donald B; Wszolek Zbigniew K; Stoessl A Jon
CS Pacific Parkinson's Research Centre, TRIUMF, Vancouver, BC, Canada.
SO Brain : a journal of neurology, (2005 Dec) Vol. 128, No. Pt 12, pp. 2777-85. Electronic Publication: 2005-08-04.
Journal code: 0372537. E-ISSN: 1460-2156.
CY England: United Kingdom
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200601
ED Entered STN: 29 Nov 2005
Last Updated on STN: 27 Jan 2006
Entered Medline: 26 Jan 2006

L10 ANSWER 3 OF 5 MEDLINE on STN
Full Text
AN 2005422029 MEDLINE
DN PubMed ID: 16087769
TI Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6.
AU Wullner Ullrich; Reimold Michael; Abele Michael; Burk Katrin; Minnerop Martina; Dohmen Bernd-Michael; Machulla Hans-Juergen; Bares Roland; Klockgether Thomas
CS Department of Neurology, University of Bonn, Bonn, Germany.. wuellner@uni-bonn.de
SO Archives of neurology, (2005 Aug) Vol. 62, No. 8, pp. 1280-5.
Journal code: 0372436. ISSN: 0003-9942.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200509
ED Entered STN: 10 Aug 2005
Last Updated on STN: 9 Sep 2005
Entered Medline: 8 Sep 2005

L10 ANSWER 4 OF 5 MEDLINE on STN
Full Text
AN 2004240728 MEDLINE
DN PubMed ID: 14689241
TI Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves.
AU Reimold M; Mueller-Schauenburg W; Becker G A; Reischl G; Dohmen B M; Bares R
CS Department of Nuclear Medicine, University of Tubingen, Otfried-Muller-Strasse 14, 72076 Tubingen, Germany.. matthias.reimold@uni-tuebingen.de
SO European journal of nuclear medicine and molecular imaging, (2004 Apr) Vol. 31, No. 4, pp. 564-77. Electronic Publication: 2003-12-19.
Journal code: 101140988. ISSN: 1619-7070.
CY Germany: Germany, Federal Republic of
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(VALIDATION STUDIES)
LA English
FS Priority Journals
EM 200501
ED Entered STN: 14 May 2004
Last Updated on STN: 4 Jan 2005
Entered Medline: 3 Jan 2005

L10 ANSWER 5 OF 5 MEDLINE on STN
Full Text
AN 2001676629 MEDLINE
DN PubMed ID: 11717374
TI Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.
AU Volkow N D; Chang L; Wang G J; Fowler J S; Franceschi D; Sedler M; Gatley S J; Miller E; Hitzemann R; Ding Y S; Logan J
CS Medical and Chemistry Departments, Brookhaven National Laboratory, Upton, New York 11973, USA.. volkow@bnl.gov
NC DA00280 (NIDA)
DA06891 (NIDA)
DA7092-01 (NIDA)
MO1 RR10710 (NCRR)
MO1RR 00425 (NCRR)
SO The Journal of neuroscience : the official journal of the Society for Neuroscience, (2001 Dec 1) Vol. 21, No. 23, pp. 9414-8.
Journal code: 8102140. E-ISSN: 1529-2401.
CY United States
DT (CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200201
ED Entered STN: 28 Nov 2001
Last Updated on STN: 25 Jan 2002
Entered Medline: 11 Jan 2002

=> d an ti so ab kwic 5

L11 ANSWER 5 OF 8 MEDLINE on STN
Full Text
AN 2005114124 MEDLINE
TI Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to **Parkinson**'s disease.
SO Neurochemistry international, (2005 Mar) Vol. 46, No. 4, pp. 329-35.
Electronic Publication: 2005-01-17.
Journal code: 8006959. ISSN: 0197-0186.
AB **Parkinson**'s disease is a neurodegenerative disorder associated with progressive loss of dopaminergic cells in the substantia nigra. Oxidative stress has been implicated in the pathogenesis of the disease, and dopamine has been suggested as a contributing factor that generates reactive oxygen species due to its unstable catechol moiety. We have previously shown that tetrahydrobiopterin (BH4), an obligatory cofactor for dopamine synthesis, also contributes to the vulnerability of dopamine-producing cells by generating oxidative stress. This study shows that the presence of dopamine in the cytosol enhances the cell's vulnerability to BH4. Upon exposure to ketanserin, a vesicular **monoamine transporter inhibitor**, BH4-induced dopaminergic cell death is exacerbated, accompanied by increased lipid peroxidation and protein bound quinone. While intracellular amount of DOPAC is elevated by ketanserin, the monoamine oxidase inhibitor pargyline showed no significant protection. Instead, the thiol agent N-acetylcysteine and quinone reductase inducer dimethyl fumarate abolish BH4/ketanserin-induced cell death, suggesting that quinone production plays an important role. Therefore, it can be concluded that the presence of dopamine in the cytosol seems to contribute to the cells' vulnerability to BH4 and that vesicular monoamine transporter plays a protective role in dopaminergic cells by sequestering dopamine not only from monoamine oxidase but also from BH4-induced oxidative stress.
TI Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to **Parkinson**'s disease.
AB **Parkinson**'s disease is a neurodegenerative disorder associated with progressive loss of dopaminergic cells in the substantia nigra. Oxidative stress has been. . . that the presence of dopamine in the cytosol enhances the cell's vulnerability to BH4. Upon exposure to ketanserin, a

vesicular **monoamine transporter inhibitor**, BH4-induced dopaminergic cell death is exacerbated, accompanied by increased lipid peroxidation and protein bound quinone. While intracellular amount of DOPAC. . .

CT . . . pharmacology
Neurons: DE, drug effects
*Neurons: ME, metabolism
Neurons: PA, pathology
Oxidative Stress: DE, drug effects
*Oxidative Stress: PH, physiology
***Parkinson Disease: ME, metabolism**
Parkinson Disease: PP, physiopathology
*Substantia Nigra: ME, metabolism
Substantia Nigra: PA, pathology
Substantia Nigra: PP, physiopathology
Vesicular Biogenic Amine Transport. . .

=> d his

(FILE 'HOME' ENTERED AT 17:50:04 ON 07 JUN 2007)

FILE 'REGISTRY' ENTERED AT 17:50:40 ON 07 JUN 2007
E D-THREO-METHYLPHENIDATE/CN
L1 1 S E3

FILE 'MRCK' ENTERED AT 17:51:16 ON 07 JUN 2007
L2 1 S L1

FILE 'MEDLINE' ENTERED AT 17:51:45 ON 07 JUN 2007
L3 34 S MONOAMINE TRANSPORT? INHIBIT?
L4 51353 S PARKINSON?
L5 0 S L1
L6 46 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)
L7 80 S L3 OR L6
L8 0 S L3 AND L6
L9 3 S L3 AND L4
L10 5 S L4 AND L6
L11 8 S L4 AND L7

=> d l10 an ti so ab kwic 5

L10 ANSWER 5 OF 5 MEDLINE on STN
Full Text
AN 2001676629 MEDLINE
TI Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.
SO The Journal of neuroscience : the official journal of the Society for Neuroscience, (2001 Dec 1) Vol. 21, No. 23, pp. 9414-8.
Journal code: 8102140. E-ISSN: 1529-2401.
AB Methamphetamine is a popular drug of abuse that is neurotoxic to dopamine (DA) terminals when administered to laboratory animals. Studies in methamphetamine abusers have also documented significant loss of DA transporters (used as markers of the DA terminal) that are associated with slower motor function and decreased memory. The extent to which the loss of DA transporters predisposes methamphetamine abusers to neurodegenerative disorders such as **Parkinsonism** is unclear and may depend in part on the degree of recovery. Here we assessed the effects of protracted abstinence on the loss of DA transporters in striatum, in methamphetamine abusers using positron emission tomography and [(11)C]**d-threo-methylphenidate** (DA transporter radioligand). Brain DA transporters in five methamphetamine abusers evaluated during short abstinence (<6 months) and then retested during protracted abstinence (12-17 months) showed significant increases with protracted abstinence (caudate, +19%; putamen, +16%). Although performance in some of the tests for which we observed an association with DA transporters showed some improvement, this effect was not significant. The DA transporter increases with abstinence could indicate that methamphetamine-induced DA transporter loss reflects temporary adaptive changes (i.e., downregulation), that the loss reflects DA terminal damage but that terminals can recover, or that remaining viable terminals increase synaptic arborization. Because neuropsychological tests did not improve to the same extent, this suggests that the increase of the DA transporters

was not sufficient for complete function recovery. These findings have treatment implications because they suggest that protracted abstinence may reverse some of methamphetamine-induced alterations in brain DA terminals.
AB . . . and decreased memory. The extent to which the loss of DA transporters predisposes methamphetamine abusers to neurodegenerative disorders such as **Parkinsonism** is unclear and may depend in part on the degree of recovery. Here we assessed the effects of protracted abstinence on the loss of DA transporters in striatum, in methamphetamine abusers using positron emission tomography and [(11)C]**d-threo-methylphenidate** (DA transporter radioligand). Brain DA transporters in five methamphetamine abusers evaluated during short abstinence (<6 months) and then retested during. . .

```
=> file ca
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      5.87      17.07

FILE 'CA' ENTERED AT 17:58:33 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 31 May 2007 VOL 146 ISS 24
FILE LAST UPDATED: 31 May 2007  (20070531/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 17:50:04 ON 07 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 17:50:40 ON 07 JUN 2007
                E D-THREO-METHYLPHENIDATE/CN
L1             1 S E3

     FILE 'MRCK' ENTERED AT 17:51:16 ON 07 JUN 2007
L2             1 S L1

     FILE 'MEDLINE' ENTERED AT 17:51:45 ON 07 JUN 2007
L3            34 S MONOAMINE TRANSPORT? INHIBIT?
L4         51353 S PARKINSON?
L5             0 S L1
L6            46 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)
L7            80 S L3 OR L6
L8             0 S L3 AND L6
L9             3 S L3 AND L4
L10            5 S L4 AND L6
L11            8 S L4 AND L7

     FILE 'CA' ENTERED AT 17:58:33 ON 07 JUN 2007

=> s l1
L12          108 L1

=> s (d-threo-methylphenidate or dexmethylphenidate)/ab,bi
```

```
       2079693 D/AB
          8950 THREO/AB
          1605 METHYLPHENIDATE/AB
            34 D-THREO-METHYLPHENIDATE/AB
                 ((D(W)THREO(W)METHYLPHENIDATE)/AB)
       2351326 D/BI
         10710 THREO/BI
          2003 METHYLPHENIDATE/BI
            59 D-THREO-METHYLPHENIDATE/BI
                 ((D(W)THREO(W)METHYLPHENIDATE)/BI)
            12 DEXMETHYLPHENIDATE/AB
            17 DEXMETHYLPHENIDATE/BI
L13         74 (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)/AB,BI

=> s parkinson?/ab,bi
         18793 PARKINSON?/AB
         25539 PARKINSON?/BI
L14      25539 PARKINSON?/AB,BI

=> s l12 and l14
L15          3 L12 AND L14

=> s l3 and l14
         25989 MONOAMINE
        795021 TRANSPORT?
       1883900 INHIBIT?
            76 MONOAMINE TRANSPORT? INHIBIT?
                 (MONOAMINE(W)TRANSPORT?(W)INHIBIT?)
L16          6 L3 AND L14

=> d 1-6

L16  ANSWER 1 OF 6  CA  COPYRIGHT 2007 ACS on STN
Full Text
AN   145:78  CA
TI   Neurotoxic effects of drugs of abuse: imaging and mechanisms
AU   Wong, Dean F.
CS   The Russell H. Morgan Department of Radiology and Radiological Science,
     Psychiatry and Environmental Health Sciences, Johns Hopkins University
     Medical School and Bloomberg School of Public Health, Baltimore, MD,
     21287, USA
SO   Cell Biology of Addiction (2006), 111-134.  Editor(s): Madras, Bertha K.
     Publisher: Cold Spring Harbor Laboratory Press, Woodbury, N. Y.
     CODEN: 69HTL4; ISBN: 0-87969-753-9
DT   Conference; General Review
LA   English
RE.CNT  76    THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16  ANSWER 2 OF 6  CA  COPYRIGHT 2007 ACS on STN
Full Text
AN   142:295947  CA
TI   Inhibition of vesicular monoamine transporter enhances vulnerability of
     dopaminergic cells: relevance to Parkinson's disease
AU   Choi, Hyun Jin; Lee, So Yeon; Cho, Yuri; Hwang, Onyou
CS   Department of Biochemistry and Molecular Biology, University of Ulsan
     College of Medicine, Seoul, 138-736, S. Korea
SO   Neurochemistry International (2005), 46(4), 329-335
     CODEN: NEUIDS; ISSN: 0197-0186
PB   Elsevier B.V.
DT   Journal
LA   English
RE.CNT  46    THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16  ANSWER 3 OF 6  CA  COPYRIGHT 2007 ACS on STN
Full Text
AN   139:85526  CA
TI   Preparation of tropane analogs for use in pharmaceutical compositions for
     inhibition of monamine transport
IN   Meltzer, Peter Claude; Madras, Bertha Kalifon; Blundell, Paul
PA   USA
```

SO Brit. UK Pat. Appl., 92 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2383581	A	20030702	GB 2001-31008	20011227
	GB 2383581	B	20060719		
	CA 2366256	A1	20030409	CA 2001-2366256	20011227
	JP 2003119194	A	20030423	JP 2001-396980	20011227
	US 2003105125	A1	20030605	US 2001-33621	20011227
	US 7199132	B2	20070403		
	AU 200197489	A	20030410	AU 2001-97489	20011228
	AU 782622	B2	20050818		
	KR 2006102311	A	20060927	KR 2006-86286	20060907
PRAI	US 2001-327963P	P	20011009		
	KR 2001-86717	A3	20011228		

OS MARPAT 139:85526
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 138:363109 CA
TI Effects of inhibitors for vesicular monoamine transporter (VMAT) on apoptosis of PC12 cell
AU Dong, Hairong; Ye, Min; Ding, Xinsheng
CS The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, 210029, Peop. Rep. China
SO Nanjing Yike Daxue Xuebao (2002), 22(2), 116-118
CODEN: NYDXFS; ISSN: 1007-4368
PB Nanjing Yike Daxue
DT Journal
LA Chinese

L16 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 110:19597 CA
TI Characteristics of the transport of the quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules
AU Darchen, Francois; Scherman, Daniel; Desnos, Claire; Henry, Jean Pierre
CS Inst. Biol. Phys. Chim., Paris, 75005, Fr.
SO Biochemical Pharmacology (1988), 37(22), 4381-7
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L16 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 109:142045 CA
TI 4,4-Diphenylpiperidine derivatives and their sila analogs. A comparative study of their interaction with neural receptor binding sites and synaptosomal monoamine uptake
AU Stasch, J. P.; Russ, H.; Schacht, U.; Witteler, M.; Neuser, D.; Gerlach, M.; Leven, M.; Kuhn, W.; Jutzi, P.; Przuntek, H.
CS Dep. Neurol., Univ. Wuerzburg/Main, Wuerzburg, Fed. Rep. Ger.
SO Arzneimittel-Forschung (1988), 38(8), 1075-8
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English

=> d an ti so ab kwic 3 4 6

L16 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 139:85526 CA
TI Preparation of tropane analogs for use in pharmaceutical compositions for inhibition of monamine transport
SO Brit. UK Pat. Appl., 92 pp.
CODEN: BAXXDU

AB New tropane analogs, such as I [R1 = carboxy, acyl, alkyl, alkenyl, alkynyl, carboxamide; R2 = 6- or 7-OH, -oxo; Ar = unsubstituted- or substituted-Ph, naphthyl, anthracenyl, phenanthracenyl, benzhydryl; 2,3-single or double bond], were prepd. for therapeutic uses as inhibitors of monoamine transporters. These tropane analogs are intended for treatment of disorders involving dopamine, serotonin, or norepinephrine transport, such as migraine, cocaine abuse, psychiatric disorders such as depression, neurodegenerative diseases such as **Parkinson**'s and Alzheimer's diseases. Thus, tropane II was prepd. via a multistep synthetic sequence which began with a cycloaddn. reaction of acetonedicarboxylic acid anhydride with 2,5-dihydro-2,5-dimethoxyfuran to form the target tropane ring and subsequent coupling reaction of the corresponding intermediate 3-triflate with 3,4-C6H3B(OH)2. Certain preferred compds. of the present invention have a high selectivity for the dopamine transporters vs. the serotonin transporters. Also described are pharmaceutical therapeutic compns. comprising the compds. and a method for inhibiting 5-hydroxytryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a inhibiting amt. of a compd. of the present invention.

AB . . . involving dopamine, serotonin, or norepinephrine transport, such as migraine, cocaine abuse, psychiatric disorders such as depression, neurodegenerative diseases such as **Parkinson**'s and Alzheimer's diseases. Thus, tropane II was prepd. via a multistep synthetic sequence which began with a cycloaddn. reaction of. . .

ST . . . prepn; psychiatric disorder treatment tropane analog prepn; drug abuse cocaine treatment tropane analog prepn; Alzheimer disease treatment tropane analog prepn; **Parkinson** disease treatment tropane analog prepn; depression treatment tropane analog prepn; neurodegenerative disease treatment tropane analog prepn; hydroxytryptamine reuptake inhibitor tropane. . .

IT Drugs of abuse
(abuse of, treatment; prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT Nervous system, disease
(degeneration, treatment; prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT Mental and behavioral disorders
(depression, treatment; prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine transporter; prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(norepinephrine transporter; prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 5-HT reuptake inhibitors
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serotonin transporter; prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT Alzheimer's disease
Mental and behavioral disorders
Parkinson's disease
(treatment; prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 50-36-2, Cocaine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(abuse, treatment; prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 552839-56-2P 552839-57-3P
RL: BYP (Byproduct); PREP (Preparation)
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 74163-84-1P 143965-99-5P 157136-88-4P 192461-06-6P 357924-51-7P 357924-52-8P 357924-53-9P 357924-54-0P 357924-75-5P 357924-82-4P 357924-83-5P
RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 357924-60-8P
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 211047-07-3P 357924-86-8P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 187963-14-0P 187963-15-1P 187963-40-2P 187963-42-4P 357925-01-0P
357925-02-1P 552839-60-8P 552839-61-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 187963-13-9P 187963-28-6P 187963-32-2P 187963-34-4P 187963-36-6P
187963-38-8P 211047-06-2P 357924-55-1P 357924-56-2P 357924-57-3P
357924-58-4P 357924-59-5P 357924-61-9P 357924-62-0P 357924-63-1P
357924-64-2P 357924-76-6P 357924-77-7P 357924-78-8P 357924-79-9P
357924-80-2P 357924-84-6P 357924-85-7P 357924-87-9P 357924-88-0P
357924-89-1P 357924-90-4P 357924-95-9P 357924-96-0P 357925-03-2P
357925-04-3P 357925-07-6P 357925-08-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 65-85-0, Benzoic acid, reactions 98-80-6 332-77-4,
2,5-Dimethoxy-2,5-dihydrofuran 365-24-2 542-05-2 925-90-6,
Ethylmagnesium bromide 1765-93-1 32316-92-0 39637-74-6 151169-75-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 10521-08-1P, Acetonedicarboxylic acid anhydride 187963-20-8P
187963-22-0P 187963-24-2P 187963-26-4P 187963-46-8P 187963-47-9P
187963-48-0P 187963-49-1P 187963-50-4P 187963-51-5P 187963-52-6P
187963-53-7P 187963-54-8P 187963-56-0P 357924-47-1P 357924-48-2P
357924-49-3P 357924-50-6P 357924-65-3P 357924-66-4P 357924-67-5P
357924-68-6P 357924-69-7P 357924-70-0P 357924-71-1P 357924-72-2P
357924-91-5P 357924-92-6P 357924-93-7P 357924-94-8P 357924-97-1P
357924-98-2P 357924-99-3P 552839-58-4P 552839-59-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 552839-62-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

IT 50-67-9, 5-Hydroxytryptamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(re-uptake inhibitor; prepn. of tropane analogs for therapeutic use as **monoamine transport inhibitors**)

L16 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 138:363109 CA
TI Effects of inhibitors for vesicular monoamine transporter (VMAT) on apoptosis of PC12 cell
SO Nanjing Yike Daxue Xuebao (2002), 22(2), 116-118
CODEN: NYDXFS; ISSN: 1007-4368
AB Studies were carried out to examine the mechanisms for apoptosis and necrosis of dopamine neurons in **Parkinson**'s disease. The effect of VMAT inhibitor, reserpine, on apoptosis of PC12 cells was obsd. with MTT and Flow Cytometer. Reserpine alone had no cytotoxic effect on PC12 cells.

Dopamine, however, was cytotoxic to PC12 cells at concns. greater than 0.03 mmol/L. Reserpine combined with dopamine to form a synergistic toxic effect on PC12 cells. The apoptosis ratio of PC12 cells was markedly increased when these cells were treated with the same concn. of dopamine combined with reserpine. Cells treated with lower concn. of dopamine (0.015 mmol/L) combined with reserpine also had decreased survival rates. Thus, the VMAT inhibitor renders dopamine an endogenous toxin and induces apoptosis of dopamine neurons.

AB Studies were carried out to examine the mechanisms for apoptosis and necrosis of dopamine neurons in **Parkinson**'s disease. The effect of VMAT inhibitor, reserpine, on apoptosis of PC12 cells was obsd. with MTT and Flow Cytometer. Reserpine. . .

ST vesicular **monoamine transporter inhibitor** dopamine neuron apoptosis **parkinsonism**

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VMAT (vesicular monoamine transporter); vesicular **monoamine transporter inhibitors** and dopamine effect on apoptosis of PC12 cell in **Parkinson**'s disease model)

IT Nerve
(dopaminergic; vesicular **monoamine transporter inhibitors** and dopamine effect on apoptosis of PC12 cell in **Parkinson**'s disease model)

IT Cell death
(neuron; vesicular **monoamine transporter inhibitors** and dopamine effect on apoptosis of PC12 cell in **Parkinson**'s disease model)

IT Apoptosis
Neuron
Parkinson's disease
(vesicular **monoamine transporter inhibitors** and dopamine effect on apoptosis of PC12 cell in **Parkinson**'s disease model)

IT 51-61-6, Dopamine, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(vesicular **monoamine transporter inhibitors** and dopamine effect on apoptosis of PC12 cell in **Parkinson**'s disease model)

L16 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN
Full Text

AN 109:142045 CA

TI 4,4-Diphenylpiperidine derivatives and their sila analogs. A comparative study of their interaction with neural receptor binding sites and synaptosomal monoamine uptake

SO Arzneimittel-Forschung (1988), 38(8), 1075-8
CODEN: ARZNAD; ISSN: 0004-4172

AB The potential anti-**Parkinson** drugs 1-R-4,4-diphenylpiperidines I (R = H, Me, Pr, or Bu) and 1-R-4,4-diphenyl-4-sila-piperidines II (R = H, Me, Pr, or Bu) were evaluated for their neuroreceptor affinity with respect to their structure-activity relationship in rat brain prepns. In these compds., substitution of the central C at position 4 by Si leads to more lipophilic substances. While the binding of these compds. to dopamine, serotonin and GABA/benzodiazepine receptors is relatively nonspecific, the binding to the μ- and δ-subtypes of opiate receptors and to the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site show probably pharmacol. relevant effects. In almost all cases, the Si-contg. compds. have a slightly higher receptor affinity than the corresponding C-contg. compds. The studies on the uptake sites for the biogenic amines noradrenaline, dopamine and serotonin, on the other hand, reveal some considerable differences between the C- and Si-contg. analogs. The 4,4-diphenyl-4-sila-piperidine has much stronger uptake inhibiting properties for noradrenaline and serotonin than the corresponding C-contg. compds.

AB The potential anti-**Parkinson** drugs 1-R-4,4-diphenylpiperidines I (R = H, Me, Pr, or Bu) and 1-R-4,4-diphenyl-4-sila-piperidines II (R = H, Me, Pr, or Bu). . .

IT Molecular structure-biological activity relationship
(**monoamine transport-inhibiting**, of diphenylpiperidine derivs. and their sila analogs)

IT Molecular structure-biological activity relationship

(**monoamine transport-inhibiting**, of
diphenylpiperidine derivs. and their sila analogs, in nerve)

```
=> d his

     (FILE 'HOME' ENTERED AT 17:50:04 ON 07 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 17:50:40 ON 07 JUN 2007
               E D-THREO-METHYLPHENIDATE/CN
L1             1 S E3

     FILE 'MRCK' ENTERED AT 17:51:16 ON 07 JUN 2007
L2             1 S L1

     FILE 'MEDLINE' ENTERED AT 17:51:45 ON 07 JUN 2007
L3            34 S MONOAMINE TRANSPORT? INHIBIT?
L4         51353 S PARKINSON?
L5             0 S L1
L6            46 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)
L7            80 S L3 OR L6
L8             0 S L3 AND L6
L9             3 S L3 AND L4
L10            5 S L4 AND L6
L11            8 S L4 AND L7

     FILE 'CA' ENTERED AT 17:58:33 ON 07 JUN 2007
L12          108 S L1
L13           74 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)/AB,BI
L14        25539 S PARKINSON?/AB,BI
L15            3 S L12 AND L14
L16            6 S L3 AND L14

=> d l16 1-6

L16  ANSWER 1 OF 6  CA  COPYRIGHT 2007 ACS on STN
Full Text
AN   145:78  CA
TI   Neurotoxic effects of drugs of abuse: imaging and mechanisms
AU   Wong, Dean F.
CS   The Russell H. Morgan Department of Radiology and Radiological Science,
     Psychiatry and Environmental Health Sciences, Johns Hopkins University
     Medical School and Bloomberg School of Public Health, Baltimore, MD,
     21287, USA
SO   Cell Biology of Addiction (2006), 111-134.  Editor(s): Madras, Bertha K.
     Publisher: Cold Spring Harbor Laboratory Press, Woodbury, N. Y.
     CODEN: 69HTL4; ISBN: 0-87969-753-9
DT   Conference; General Review
LA   English
RE.CNT  76    THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16  ANSWER 2 OF 6  CA  COPYRIGHT 2007 ACS on STN
Full Text
AN   142:295947  CA
TI   Inhibition of vesicular monoamine transporter enhances vulnerability of
     dopaminergic cells: relevance to Parkinson's disease
AU   Choi, Hyun Jin; Lee, So Yeon; Cho, Yuri; Hwang, Onyou
CS   Department of Biochemistry and Molecular Biology, University of Ulsan
     College of Medicine, Seoul, 138-736, S. Korea
SO   Neurochemistry International (2005), 46(4), 329-335
     CODEN: NEUIDS; ISSN: 0197-0186
PB   Elsevier B.V.
DT   Journal
LA   English
RE.CNT  46    THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16  ANSWER 3 OF 6  CA  COPYRIGHT 2007 ACS on STN
Full Text
AN   139:85526  CA
TI   Preparation of tropane analogs for use in pharmaceutical compositions for
```

inhibition of monamine transport
IN Meltzer, Peter Claude; Madras, Bertha Kalifon; Blundell, Paul
PA USA
SO Brit. UK Pat. Appl., 92 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2383581	A	20030702	GB 2001-31008	20011227
	GB 2383581	B	20060719		
	CA 2366256	A1	20030409	CA 2001-2366256	20011227
	JP 2003119194	A	20030423	JP 2001-396980	20011227
	US 2003105125	A1	20030605	US 2001-33621	20011227
	US 7199132	B2	20070403		
	AU 200197489	A	20030410	AU 2001-97489	20011228
	AU 782622	B2	20050818		
	KR 2006102311	A	20060927	KR 2006-86286	20060907
PRAI	US 2001-327963P	P	20011009		
	KR 2001-86717	A3	20011228		

OS MARPAT 139:85526
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 138:363109 CA
TI Effects of inhibitors for vesicular monoamine transporter (VMAT) on apoptosis of PC12 cell
AU Dong, Hairong; Ye, Min; Ding, Xinsheng
CS The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, 210029, Peop. Rep. China
SO Nanjing Yike Daxue Xuebao (2002), 22(2), 116-118
CODEN: NYDXFS; ISSN: 1007-4368
PB Nanjing Yike Daxue
DT Journal
LA Chinese

L16 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 110:19597 CA
TI Characteristics of the transport of the quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules
AU Darchen, Francois; Scherman, Daniel; Desnos, Claire; Henry, Jean Pierre
CS Inst. Biol. Phys. Chim., Paris, 75005, Fr.
SO Biochemical Pharmacology (1988), 37(22), 4381-7
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L16 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 109:142045 CA
TI 4,4-Diphenylpiperidine derivatives and their sila analogs. A comparative study of their interaction with neural receptor binding sites and synaptosomal monoamine uptake
AU Stasch, J. P.; Russ, H.; Schacht, U.; Witteler, M.; Neuser, D.; Gerlach, M.; Leven, M.; Kuhn, W.; Jutzi, P.; Przuntek, H.
CS Dep. Neurol., Univ. Wuerzburg/Main, Wuerzburg, Fed. Rep. Ger.
SO Arzneimittel-Forschung (1988), 38(8), 1075-8
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English

=> d kwic 6

L16 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN
AB The potential anti-**Parkinson** drugs 1-R-4,4-diphenylpiperidines I (R = H, Me, Pr, or Bu) and 1-R-4,4-diphenyl-4-sila-piperidines II (R = H, Me, Pr, or Bu). . .

IT Molecular structure-biological activity relationship
(**monoamine transport-inhibiting**, of
diphenylpiperidine derivs. and their sila analogs)
IT Molecular structure-biological activity relationship
(**monoamine transport-inhibiting**, of
diphenylpiperidine derivs. and their sila analogs, in nerve)

=> d his

(FILE 'HOME' ENTERED AT 17:50:04 ON 07 JUN 2007)

FILE 'REGISTRY' ENTERED AT 17:50:40 ON 07 JUN 2007
E D-THREO-METHYLPHENIDATE/CN
L1 1 S E3

FILE 'MRCK' ENTERED AT 17:51:16 ON 07 JUN 2007
L2 1 S L1

FILE 'MEDLINE' ENTERED AT 17:51:45 ON 07 JUN 2007
L3 34 S MONOAMINE TRANSPORT? INHIBIT?
L4 51353 S PARKINSON?
L5 0 S L1
L6 46 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)
L7 80 S L3 OR L6
L8 0 S L3 AND L6
L9 3 S L3 AND L4
L10 5 S L4 AND L6
L11 8 S L4 AND L7

FILE 'CA' ENTERED AT 17:58:33 ON 07 JUN 2007
L12 108 S L1
L13 74 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)/AB,BI
L14 25539 S PARKINSON?/AB,BI
L15 3 S L12 AND L14
L16 6 S L3 AND L14

=> s l13 and l14
L17 1 L13 AND L14

=> d

L17 ANSWER 1 OF 1 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 140:281401 CA
TI Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of **Parkinson**'s disease
IN Fleckenstein, Annette E.; Hanson, Glen R.
PA University of Utah Research Foundation, USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026258	A2	20040401	WO 2003-US29668	20030919
	WO 2004026258	A3	20040624		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499601	A1	20040401	CA 2003-2499601	20030919
	AU 2003272608	A1	20040408	AU 2003-272608	20030919
	US 2006241082	A1	20061026	US 2005-528684	20050509
PRAI	US 2002-412439P	P	20020919		

```
    WO 2003-US29668      W     20030919
OS  MARPAT 140:281401


=> file uspatall
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    54.16      71.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -2.92      -2.92

FILE 'USPATFULL' ENTERED AT 18:03:33 ON 07 JUN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:03:33 ON 07 JUN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1
L18          63 L1

=> s (d-threo-methylphenidate or dexmethylphenidate)
L19         143 (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)

=> s parkinson?
L20       31993 PARKINSON?

=> s l18 and l20
L21           4 L18 AND L20

=> s l19 and l20
L22          29 L19 AND L20

=> s (d-threo-methylphenidate or dexmethylphenidate)/clm
L23          61 (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)/CLM

=> s parkinson?/clm
L24        6024 PARKINSON?/CLM

=> s l23 and l24
L25           2 L23 AND L24

=> d 1-2

L25  ANSWER 1 OF 2  USPATFULL on STN
Full Text
AN      2007:135187  USPATFULL
TI      Methods for treating coginitive impairment and improving cognition
IN      Epstein, Mel H., Bristol, RI, UNITED STATES
        Wiig, Kjesten A., Providence, RI, UNITED STATES
        Carpenter, Randall L., Waban, MA, UNITED STATES
        Zarevics, Peter, Spring City, PA, UNITED STATES
        Arnold, H. Moore, Lower Gwynedd, PA, UNITED STATES
PA      Cognition Pharmaceuticals LLC (U.S. corporation)
PI      US 2007117869        A1  20070524
AI      US 2004-557095       A1  20040521 (10)
        WO 2004-US15974          20040521
                                 20060303  PCT 371 date
RLI     Continuation-in-part of Ser. No. US 2003-444970, filed on 23 May 2003,
        ABANDONED Continuation-in-part of Ser. No. US 2002-139606, filed on 2
        May 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-3740, filed
        on 31 Oct 2001, GRANTED, Pat. No. US 6828351 Continuation-in-part of
        Ser. No. US 2004-791223, filed on 2 Mar 2004, PENDING
        Continuation-in-part of Ser. No. US 2003-444970, filed on 23 May 2003,
        ABANDONED Continuation-in-part of Ser. No. US 2002-139606, filed on 2
        May 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-3740, filed
        on 31 Oct 2001, GRANTED, Pat. No. US 6828351
PRAI    WO 2003-US45793      20011031
        US 2000-245323P      20001101 (60)
        US 2003-473168P      20030523 (60)
        US 2000-245323P      20001101 (60)
```

```
DT     Utility
FS     APPLICATION
LN.CNT 6628
INCL   INCLM: 514/649.000
NCL    NCLM:  514/649.000
IC     IPCI   A61K0031-137 [I,A]

L25  ANSWER 2 OF 2  USPATFULL on STN
Full Text
AN     2006:282139  USPATFULL
TI     Modulating vesicular monoamine transporter trafficking and function: a
       novel approach for the treatment of parkinson's disease
IN     Fleckenstein, Annette E, 757 Shady Creek Place, Salt Lake City, UT,
       UNITED STATES  84106
       Hanson, Glen R., UNITED STATES
PI     US 2006241082       A1  20061026
AI     US 2003-528684      A1  20030919 (10)
       WO 2003-US29668         20030919
                               20050509  PCT 371 date
PRAI   US 2002-412439P     20020919 (60)
DT     Utility
FS     APPLICATION
LN.CNT 5539
INCL   INCLM: 514/089.000
       INCLS: 514/317.000; 514/367.000; 514/227.500; 514/237.500; 514/252.120
NCL    NCLM:  514/089.000
       NCLS:  514/227.500; 514/237.500; 514/252.120; 514/317.000; 514/367.000
IC     IPCI   A61K0031-675 [I,A]; A61K0031-54 [I,A]; A61K0031-537 [I,A];
              A61K0031-445 [I,A]; A61K0031-495 [I,A]; A61K0031-428 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 17:50:04 ON 07 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 17:50:40 ON 07 JUN 2007
                E D-THREO-METHYLPHENIDATE/CN
L1             1 S E3

     FILE 'MRCK' ENTERED AT 17:51:16 ON 07 JUN 2007
L2             1 S L1

     FILE 'MEDLINE' ENTERED AT 17:51:45 ON 07 JUN 2007
L3            34 S MONOAMINE TRANSPORT? INHIBIT?
L4         51353 S PARKINSON?
L5             0 S L1
L6            46 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)
L7            80 S L3 OR L6
L8             0 S L3 AND L6
L9             3 S L3 AND L4
L10            5 S L4 AND L6
L11            8 S L4 AND L7

     FILE 'CA' ENTERED AT 17:58:33 ON 07 JUN 2007
L12          108 S L1
L13           74 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)/AB,BI
L14        25539 S PARKINSON?/AB,BI
L15            3 S L12 AND L14
L16            6 S L3 AND L14
L17            1 S L13 AND L14

     FILE 'USPATFULL, USPAT2' ENTERED AT 18:03:33 ON 07 JUN 2007
L18           63 S L1
L19          143 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)
L20        31993 S PARKINSON?
L21            4 S L18 AND L20
L22           29 S L19 AND L20
L23           61 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)/CLM
L24         6024 S PARKINSON?/CLM
L25            2 S L23 AND L24
```

```
=> d l21 1-4

L21  ANSWER 1 OF 4  USPATFULL on STN
Full Text
AN      2006:282139  USPATFULL
TI      Modulating vesicular monoamine transporter trafficking and function: a
        novel approach for the treatment of parkinson's disease
IN      Fleckenstein, Annette E, 757 Shady Creek Place, Salt Lake City, UT,
        UNITED STATES  84106
        Hanson, Glen R., UNITED STATES
PI      US 2006241082       A1  20061026
AI      US 2003-528684      A1  20030919 (10)
        WO 2003-US29668         20030919
                                20050509  PCT 371 date
PRAI    US 2002-412439P     20020919 (60)
DT      Utility
FS      APPLICATION
LN.CNT 5539
INCL    INCLM: 514/089.000
        INCLS: 514/317.000; 514/367.000; 514/227.500; 514/237.500; 514/252.120
NCL     NCLM:  514/089.000
        NCLS:  514/227.500; 514/237.500; 514/252.120; 514/317.000; 514/367.000
IC      IPCI   A61K0031-675 [I,A]; A61K0031-54 [I,A]; A61K0031-537 [I,A];
               A61K0031-445 [I,A]; A61K0031-495 [I,A]; A61K0031-428 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21  ANSWER 2 OF 4  USPATFULL on STN
Full Text
AN      2006:196145  USPATFULL
TI      Compositions comprising O-acetylsalicyl derivatives of
        aminocarbohydrates and amino acids
IN      Yu, Ruey J., Chalfont, PA, UNITED STATES
        Van Scott, Eugene J., Abington, PA, UNITED STATES
PI      US 2006166901       A1  20060727
AI      US 2005-320530      A1  20051229 (11)
PRAI    US 2005-640225P     20050103 (60)
DT      Utility
FS      APPLICATION
LN.CNT 1682
INCL    INCLM: 514/023.000
        INCLS: 514/165.000
NCL     NCLM:  514/023.000
        NCLS:  514/165.000
IC      IPCI   A61K0031-7008 [I,A]; A61K0031-60 [I,A]
        IPCR   A61K0031-7008 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A];
               A61K0031-7008 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21  ANSWER 3 OF 4  USPATFULL on STN
Full Text
AN      2002:243602  USPATFULL
TI      Use of methylphenidate compounds to enhance memory
IN      Epstein, Mel, Bristol, RI, UNITED STATES
        Wiig, Kjesten A., Providence, RI, UNITED STATES
PI      US 2002132793       A1  20020919
AI      US 2002-87232       A1  20020228 (10)
RLI     Continuation-in-part of Ser. No. US 2001-941238, filed on 28 Aug 2001,
        PENDING
PRAI    US 2000-228478P     20000828 (60)
        US 2000-235972P     20000928 (60)
DT      Utility
FS      APPLICATION
LN.CNT 3025
INCL    INCLM: 514/079.000
        INCLS: 514/317.000; 705/002.000
NCL     NCLM:  514/079.000
        NCLS:  514/317.000; 705/002.000
IC      [7]
        ICM    A61K031-675
        ICS    A61K031-445; G06F017-60
        IPCI   A61K0031-675 [ICM,7]; A61K0031-445 [ICS,7]; G06F0017-60 [ICS,7]
        IPCR   A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0031-4458 [I,C*];
```

```
              A61K0031-4458 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21  ANSWER 4 OF 4  USPATFULL on STN
Full Text
AN     2002:192091  USPATFULL
TI     Use of threo-methylphenidate compounds to enhance memory
IN     Epstein, Mel, Bristol, RI, UNITED STATES
       Wiig, Kjesten A., Providence, RI, UNITED STATES
PI     US 2002103162       A1  20020801
AI     US 2001-941238      A1  20010828 (9)
PRAI   US 2000-228478P     20000828 (60)
       US 2000-235972P     20000928 (60)
DT     Utility
FS     APPLICATION
LN.CNT 2476
INCL   INCLM: 514/079.000
       INCLS: 514/183.000; 514/210.010; 514/315.000; 514/326.000; 514/408.000;
              514/430.000; 514/449.000
NCL    NCLM:  514/079.000
       NCLS:  514/183.000; 514/210.010; 514/315.000; 514/326.000; 514/408.000;
              514/430.000; 514/449.000
IC     [7]
       ICM    A61K031-675
       ICS    A61K031-445; A61K031-397; A61K031-40; A61K031-38
       IPCI   A61K0031-675 [ICM,7]; A61K0031-445 [ICS,7]; A61K0031-397 [ICS,7];
              A61K0031-40 [ICS,7]; A61K0031-38 [ICS,7]
       IPCR   A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0031-4458 [I,C*];
              A61K0031-4458 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l21 kwic 4

L21  ANSWER 4 OF 4  USPATFULL on STN
DETD   . . . injury, age-associated memory impairment, mild cognitive
       impairment, epilepsy, mental retardation in children, and dementia
       resulting from a disease, such as Parkinson's disease, Alzheimer's
       disease, AIDS, head trauma, Huntington's disease, Pick's disease,
       Creutzfeldt-Jakob disease, Anterior Communicating Artery Syndrome,
       hypoxia, post cardiac surgery,. . .
IT    113-45-1, Methylphenidate 40431-64-9   40572-71-2
        (methylphenidate compds. to enhance memory)


=> d his

     (FILE 'HOME' ENTERED AT 17:50:04 ON 07 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 17:50:40 ON 07 JUN 2007
                E D-THREO-METHYLPHENIDATE/CN
L1             1 S E3

     FILE 'MRCK' ENTERED AT 17:51:16 ON 07 JUN 2007
L2             1 S L1

     FILE 'MEDLINE' ENTERED AT 17:51:45 ON 07 JUN 2007
L3            34 S MONOAMINE TRANSPORT? INHIBIT?
L4         51353 S PARKINSON?
L5             0 S L1
L6            46 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)
L7            80 S L3 OR L6
L8             0 S L3 AND L6
L9             3 S L3 AND L4
L10            5 S L4 AND L6
L11            8 S L4 AND L7

     FILE 'CA' ENTERED AT 17:58:33 ON 07 JUN 2007
L12          108 S L1
L13           74 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)/AB,BI
L14        25539 S PARKINSON?/AB,BI
L15            3 S L12 AND L14
```

```
L16             6 S L3 AND L14
L17             1 S L13 AND L14

     FILE 'USPATFULL, USPAT2' ENTERED AT 18:03:33 ON 07 JUN 2007
L18            63 S L1
L19           143 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)
L20         31993 S PARKINSON?
L21             4 S L18 AND L20
L22            29 S L19 AND L20
L23            61 S (D-THREO-METHYLPHENIDATE OR DEXMETHYLPHENIDATE)/CLM
L24          6024 S PARKINSON?/CLM
L25             2 S L23 AND L24

=> d l22 1-29

L22  ANSWER 1 OF 29  USPATFULL on STN
Full Text
AN      2007:135187  USPATFULL
TI      Methods for treating coginitive impairment and improving cognition
IN      Epstein, Mel H., Bristol, RI, UNITED STATES
        Wiig, Kjesten A., Providence, RI, UNITED STATES
        Carpenter, Randall L., Waban, MA, UNITED STATES
        Zarevics, Peter, Spring City, PA, UNITED STATES
        Arnold, H. Moore, Lower Gwynedd, PA, UNITED STATES
PA      Cognition Pharmaceuticals LLC (U.S. corporation)
PI      US 2007117869        A1  20070524
AI      US 2004-557095       A1  20040521 (10)
        WO 2004-US15974          20040521
                                 20060303  PCT 371 date
RLI     Continuation-in-part of Ser. No. US 2003-444970, filed on 23 May 2003,
        ABANDONED Continuation-in-part of Ser. No. US 2002-139606, filed on 2
        May 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-3740, filed
        on 31 Oct 2001, GRANTED, Pat. No. US 6828351 Continuation-in-part of
        Ser. No. US 2004-791223, filed on 2 Mar 2004, PENDING
        Continuation-in-part of Ser. No. US 2003-444970, filed on 23 May 2003,
        ABANDONED Continuation-in-part of Ser. No. US 2002-139606, filed on 2
        May 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-3740, filed
        on 31 Oct 2001, GRANTED, Pat. No. US 6828351
PRAI    WO 2003-US45793      20011031
        US 2000-245323P      20001101 (60)
        US 2003-473168P      20030523 (60)
        US 2000-245323P      20001101 (60)
DT      Utility
FS      APPLICATION
LN.CNT 6628
INCL    INCLM: 514/649.000
NCL     NCLM:  514/649.000
IC      IPCI   A61K0031-137 [I,A]

L22  ANSWER 2 OF 29  USPATFULL on STN
Full Text
AN      2007:134496  USPATFULL
TI      Nucleic Acid-Based Matrixes for Protein Production
IN      LUO, Dan, Ithaca, NY, UNITED STATES
        Um, Soong Ho, Ithaca, NY, UNITED STATES
PI      US 2007117177        A1  20070524
AI      US 2006-464184       A1  20060811 (11)
PRAI    US 2005-722032P      20050929 (60)
        US 2006-783422P      20060317 (60)
        US 2006-783426P      20060317 (60)
        US 2005-707431P      20050811 (60)
        US 2006-745383P      20060421 (60)
        US 2006-756453P      20060105 (60)
DT      Utility
FS      APPLICATION
LN.CNT 5584
INCL    INCLM: 435/068.100
        INCLS: 435/006.000; 525/054.100
NCL     NCLM:  435/068.100
        NCLS:  435/006.000; 525/054.100
IC      IPCI   C12P0021-06 [I,A]
```

L22 ANSWER 3 OF 29 USPATFULL on STN
Full Text
AN 2007:114926 USPATFULL
TI Methods of providing neuroprotection
IN Epstein, Mel H., Bristol, RI, UNITED STATES
Wiig, Kiesten A., Providence, RI, UNITED STATES
PI US 2007100000 A1 20070503
AI US 2006-636702 A1 20061208 (11)
RLI Continuation of Ser. No. US 2006-557095, filed on 3 Mar 2006, PENDING A 371 of International Ser. No. WO 2004-US15974, filed on 21 May 2004 Continuation-in-part of Ser. No. US 2004-791223, filed on 2 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2003-444970, filed on 23 May 2003, ABANDONED Continuation-in-part of Ser. No. US 2002-139606, filed on 2 May 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-3740, filed on 31 Oct 2001, GRANTED, Pat. No. US 6828351
PRAI US 2000-245323P 20001101 (60)
DT Utility
FS APPLICATION
LN.CNT 6469
INCL INCLM: 514/649.000
NCL NCLM: 514/649.000
IC IPCI A61K0031-137 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 4 OF 29 USPATFULL on STN
Full Text
AN 2007:114925 USPATFULL
TI Methods of treating depression
IN Epstein, Mel H., Bristol, RI, UNITED STATES
Wiig, Kiesten A., Providence, RI, UNITED STATES
PI US 2007099999 A1 20070503
AI US 2006-636644 A1 20061208 (11)
RLI Continuation of Ser. No. US 2006-557095, filed on 3 Mar 2006, PENDING A 371 of International Ser. No. WO 2004-US15974, filed on 21 May 2004 Continuation-in-part of Ser. No. US 2004-791223, filed on 2 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2003-444970, filed on 23 May 2003, ABANDONED Continuation-in-part of Ser. No. US 2002-139606, filed on 2 May 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-3740, filed on 31 Oct 2001, GRANTED, Pat. No. US 6828351
PRAI US 2000-245323P 20001101 (60)
DT Utility
FS APPLICATION
LN.CNT 6455
INCL INCLM: 514/649.000
NCL NCLM: 514/649.000
IC IPCI A61K0031-137 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 5 OF 29 USPATFULL on STN
Full Text
AN 2007:101128 USPATFULL
TI METHODS AND COMPOSITIONS FOR TREATING PAIN
IN Robbins, Wendye, San Francisco, CA, UNITED STATES
PI US 2007087977 A1 20070419
AI US 2006-553924 A1 20061027 (11)
RLI Continuation-in-part of Ser. No. US 2005-281771, filed on 16 Nov 2005, PENDING
PRAI US 2004-628646P 20041116 (60)
DT Utility
FS APPLICATION
LN.CNT 4606
INCL INCLM: 514/023.000
INCLS: 514/171.000; 514/220.000; 514/027.000; 514/456.000; 514/282.000; 514/561.000; 514/217.000; 514/317.000
NCL NCLM: 514/023.000
NCLS: 514/027.000; 514/171.000; 514/217.000; 514/220.000; 514/282.000; 514/317.000; 514/456.000; 514/561.000
IC IPCI A61K0031-7048 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7008 [I,A]; A61K0031-573 [I,A]; A61K0031-57 [I,C*]; A61K0031-551 [I,A]; A61K0031-485 [I,A]; A61K0031-55 [I,A]; A61K0031-445 [I,A]; A61K0031-353 [I,A]; A61K0031-352 [I,C*]; A61K0031-195 [I,A]; A61K0031-185 [I,C*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 6 OF 29 USPATFULL on STN
Full Text
AN 2007:56672 USPATFULL
TI Isoindole-imide compounds and compositions comprising and methods of using the same
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Chen, Roger Shen-Chu, Edison, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
Ruchelman, Alexander L., Cream Ridge, NJ, UNITED STATES
PI US 2007049618 A1 20070301
AI US 2006-513563 A1 20060830 (11)
PRAI US 2005-712387P 20050831 (60)
DT Utility
FS APPLICATION
LN.CNT 9894
INCL INCLM: 514/323.000
INCLS: 546/200.000
NCL NCLM: 514/323.000
NCLS: 546/200.000
IC IPCI A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; C07D0403-04 [I,A]; C07D0403-00 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 7 OF 29 USPATFULL on STN
Full Text
AN 2007:17021 USPATFULL
TI Glucuronidated nebivolol metabolites
IN O'Donnell, John P., Morgantown, WV, UNITED STATES
Owens, Walter, Morgantown, WV, UNITED STATES
Duncan, Joseph, Morgantown, WV, UNITED STATES
Shaw, Andrew, Morgantown, WV, UNITED STATES
PI US 2007014734 A1 20070118
AI US 2006-342889 A1 20060130 (11)
PRAI US 2005-648552P 20050131 (60)
US 2006-755755P 20060103 (60)
DT Utility
FS APPLICATION
LN.CNT 3450
INCL INCLM: 424/045.000
INCLS: 514/023.000
NCL NCLM: 424/045.000
NCLS: 514/023.000
IC IPCI A61K0031-7048 [I,A]; A61K0031-7042 [I,C*]; A61L0009-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 8 OF 29 USPATFULL on STN
Full Text
AN 2007:17020 USPATFULL
TI Hydroxylated nebivolol metabolites
IN O'Donnell, John P., Morgantown, WV, UNITED STATES
Owens, Walter, Morgantown, WV, UNITED STATES
Duncan, Joseph, Morgantown, WV, UNITED STATES
Shaw, Andrew, Morgantown, WV, UNITED STATES
Wu, Jinn, Princeton Junction, NJ, UNITED STATES
PI US 2007014733 A1 20070118
AI US 2006-342497 A1 20060130 (11)
PRAI US 2005-648551P 20050131 (60)
US 2006-755856P 20060103 (60)
DT Utility
FS APPLICATION
LN.CNT 3515
INCL INCLM: 424/045.000
INCLS: 514/456.000
NCL NCLM: 424/045.000
NCLS: 514/456.000
IC IPCI A61K0031-353 [I,A]; A61K0031-352 [I,C*]; A61L0009-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 9 OF 29 USPATFULL on STN
Full Text

AN 2006:282139 USPATFULL
TI Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of **parkinson**'s disease
IN Fleckenstein, Annette E, 757 Shady Creek Place, Salt Lake City, UT, UNITED STATES 84106
Hanson, Glen R., UNITED STATES
PI US 2006241082 A1 20061026
AI US 2003-528684 A1 20030919 (10)
WO 2003-US29668 20030919
20050509 PCT 371 date
PRAI US 2002-412439P 20020919 (60)
DT Utility
FS APPLICATION
LN.CNT 5539
INCL INCLM: 514/089.000
INCLS: 514/317.000; 514/367.000; 514/227.500; 514/237.500; 514/252.120
NCL NCLM: 514/089.000
NCLS: 514/227.500; 514/237.500; 514/252.120; 514/317.000; 514/367.000
IC IPCI A61K0031-675 [I,A]; A61K0031-54 [I,A]; A61K0031-537 [I,A]; A61K0031-445 [I,A]; A61K0031-495 [I,A]; A61K0031-428 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 10 OF 29 USPATFULL on STN
Full Text
AN 2006:281165 USPATFULL
TI Multiparticulate modified release composition
IN Devane, John G., Athlone, IRELAND
Stark, Paul, Glassoh, IRELAND
Fanning, Niall M. M., Athlone, IRELAND
Rekhi, Gurvinder Singh, Suwanee, GA, UNITED STATES
Jenkins, Scott A., Downingtown, PA, UNITED STATES
Liversidge, Gary, Westchester, PA, UNITED STATES
PA Elan Corporation, plc, Dublin, IRELAND (non-U.S. corporation)
PI US 2006240105 A1 20061026
AI US 2006-372857 A1 20060310 (11)
RLI Continuation-in-part of Ser. No. US 2004-827689, filed on 19 Apr 2004, PENDING Continuation of Ser. No. US 2003-354483, filed on 30 Jan 2003, GRANTED, Pat. No. US 6793936 Continuation of Ser. No. US 2002-331754, filed on 30 Dec 2002, GRANTED, Pat. No. US 6902742 Continuation of Ser. No. US 2001-850425, filed on 7 May 2001, GRANTED, Pat. No. US 6730325 Continuation of Ser. No. US 2000-566636, filed on 8 May 2000, GRANTED, Pat. No. US 6228398 Continuation of Ser. No. WO 1999-US25632, filed on 1 Nov 1999, PENDING
PRAI US 1998-106726P 19981102 (60)
DT Utility
FS APPLICATION
LN.CNT 1712
INCL INCLM: 424/470.000
INCLS: 514/282.000; 514/570.000
NCL NCLM: 424/470.000
NCLS: 514/282.000; 514/570.000
IC IPCI A61K0031-485 [I,A]; A61K0031-192 [I,A]; A61K0031-185 [I,C*]; A61K0009-26 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 11 OF 29 USPATFULL on STN
Full Text
AN 2006:248359 USPATFULL
TI Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof
IN Yu, Ruey J., Chalfont, PA, UNITED STATES
Van Scott, Eugene J., Abington, PA, UNITED STATES
PI US 2006211754 A1 20060921
AI US 2006-375570 A1 20060315 (11)
PRAI US 2005-661921P 20050316 (60)
DT Utility
FS APPLICATION
LN.CNT 999
INCL INCLM: 514/400.000
INCLS: 514/562.000; 514/563.000
NCL NCLM: 514/400.000
NCLS: 514/562.000; 514/563.000

IC IPCI A61K0031-4172 [I,A]; A61K0031-4164 [I,C*]; A61K0031-198 [I,A]; A61K0031-185 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 12 OF 29 USPATFULL on STN
Full Text
AN 2006:241338 USPATFULL
TI Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Chen, Roger Shen-Chu, Edison, NJ, UNITED STATES
PI US 2006205787 A1 20060914
AI US 2006-338688 A1 20060125 (11)
PRAI US 2005-646505P 20050125 (60)
DT Utility
FS APPLICATION
LN.CNT 2172
INCL INCLM: 514/323.000
NCL NCLM: 514/323.000
IC IPCI A61K0031-454 [I,A]; A61K0031-4523 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 13 OF 29 USPATFULL on STN
Full Text
AN 2006:214643 USPATFULL
TI Taste masked pharmaceutical compositions
IN Wu, Chuanbin, Weston, FL, UNITED STATES
Injety, Harold, Coral Springs, FL, UNITED STATES
Weng, Tim, Cooper City, FL, UNITED STATES
PA ABRIKA PHARMACEUTICALS, INC. (U.S. corporation)
PI US 2006182796 A1 20060817
AI US 2006-346700 A1 20060203 (11)
PRAI US 2005-649644P 20050203 (60)
DT Utility
FS APPLICATION
LN.CNT 974
INCL INCLM: 424/451.000
INCLS: 424/464.000
NCL NCLM: 424/451.000
NCLS: 424/464.000
IC IPCI A61K0009-48 [I,A]; A61K0009-20 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 14 OF 29 USPATFULL on STN
Full Text
AN 2006:196145 USPATFULL
TI Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
IN Yu, Ruey J., Chalfont, PA, UNITED STATES
Van Scott, Eugene J., Abington, PA, UNITED STATES
PI US 2006166901 A1 20060727
AI US 2005-320530 A1 20051229 (11)
PRAI US 2005-640225P 20050103 (60)
DT Utility
FS APPLICATION
LN.CNT 1682
INCL INCLM: 514/023.000
INCLS: 514/165.000
NCL NCLM: 514/023.000
NCLS: 514/165.000
IC IPCI A61K0031-7008 [I,A]; A61K0031-60 [I,A]
IPCR A61K0031-7008 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]; A61K0031-7008 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 15 OF 29 USPATFULL on STN
Full Text
AN 2006:144661 USPATFULL
TI Methods and compositions using JNK inhibitors for treatment and management of central nervous system injury
IN Zeldis, Jerome B., Princeton, NJ, UNITED STATES
Faleck, Herbert, West Orange, NJ, UNITED STATES

Manning, Donald C., Bloomsbury, NJ, UNITED STATES
PI US 2006122179 A1 20060608
AI US 2005-286128 A1 20051122 (11)
PRAI US 2004-630598P 20041123 (60)
DT Utility
FS APPLICATION
LN.CNT 2465
INCL INCLM: 514/232.500
INCLS: 514/322.000; 514/383.000; 514/381.000; 514/364.000; 514/406.000
NCL NCLM: 514/232.500
NCLS: 514/322.000; 514/364.000; 514/381.000; 514/383.000; 514/406.000
IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-4245 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4196 [I,A]; A61K0031-416 [I,A]
IPCR A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-416 [I,C]; A61K0031-416 [I,A]; A61K0031-4196 [I,C]; A61K0031-4196 [I,A]; A61K0031-4245 [I,C]; A61K0031-4245 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 16 OF 29 USPATFULL on STN
Full Text
AN 2006:131806 USPATFULL
TI Methods for treating cognitive impairment in humans with multiple sclerosis
IN Epstein, Mel H., Bristol, RI, UNITED STATES
Wiig, Kjesten A., Providence, RI, UNITED STATES
Carpenter, Randall L., Waban, MA, UNITED STATES
PA Sention, Inc., Providence, RI (U.S. corporation)
PI US 2006111448 A1 20060525
AI US 2005-133144 A1 20050519 (11)
RLI Continuation-in-part of Ser. No. WO 2004-US15974, filed on 21 May 2004, PENDING Continuation-in-part of Ser. No. US 2004-791223, filed on 2 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2003-444970, filed on 23 May 2003, ABANDONED Continuation-in-part of Ser. No. US 2002-139606, filed on 2 May 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-3740, filed on 31 Oct 2001, GRANTED, Pat. No. US 6828351
PRAI WO 2001-US45793 20011031
US 2000-245323P 20001101 (60)
DT Utility
FS APPLICATION
LN.CNT 7005
INCL INCLM: 514/649.000
NCL NCLM: 514/649.000
IC IPCI A61K0031-137 [I,A]
IPCR A61K0031-137 [I,A]; A61K0031-137 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 17 OF 29 USPATFULL on STN
Full Text
AN 2006:131666 USPATFULL
TI Methods and compositions for therapeutic treatment
IN Robbins, Wendye, San Francisco, CA, UNITED STATES
PI US 2006111308 A1 20060525
AI US 2005-281984 A1 20051116 (11)
PRAI US 2004-628646P 20041116 (60)
DT Utility
FS APPLICATION
LN.CNT 4431
INCL INCLM: 514/027.000
INCLS: 514/456.000
NCL NCLM: 514/027.000
NCLS: 514/456.000
IC IPCI A61K0031-7048 [I,A]; A61K0031-7042 [I,C*]; A61K0031-353 [I,A]; A61K0031-352 [I,C*]
IPCR A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0031-352 [I,C]; A61K0031-353 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 18 OF 29 USPATFULL on STN
Full Text
AN 2006:131665 USPATFULL

```
TI     Methods and compositions for treating pain
IN     Robbins, Wendye, San Francisco, CA, UNITED STATES
PI     US 2006111307       A1  20060525
AI     US 2005-281771      A1  20051116 (11)
PRAI   US 2004-628646P     20041116 (60)
DT     Utility
FS     APPLICATION
LN.CNT 4571
INCL   INCLM: 514/027.000
       INCLS: 514/023.000; 514/220.000; 514/171.000; 514/217.000; 514/317.000;
              514/456.000; 514/561.000
NCL    NCLM:  514/027.000
       NCLS:  514/023.000; 514/171.000; 514/217.000; 514/220.000; 514/317.000;
              514/456.000; 514/561.000
IC     IPCI   A61K0031-7048 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7024 [I,A];
              A61K0031-551 [I,A]; A61K0031-55 [I,A]; A61K0031-485 [I,A];
              A61K0031-445 [I,A]
       IPCR   A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0031-445 [I,C];
              A61K0031-445 [I,A]; A61K0031-485 [I,C]; A61K0031-485 [I,A];
              A61K0031-55 [I,C]; A61K0031-55 [I,A]; A61K0031-551 [I,C];
              A61K0031-551 [I,A]; A61K0031-7024 [I,C]; A61K0031-7024 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 19 OF 29  USPATFULL on STN
Full Text
AN     2006:74778  USPATFULL
TI     Systemic administration of therapeutic amino acids and N-acetylamino
       acids
IN     Yu, Ruey J., Chalfont, PA, UNITED STATES
       Van Scott, Eugene J., Abington, PA, UNITED STATES
PI     US 2006063827       A1  20060323
AI     US 2005-228230      A1  20050919 (11)
PRAI   US 2004-612253P     20040923 (60)
       US 2004-627022P     20041112 (60)
DT     Utility
FS     APPLICATION
LN.CNT 965
INCL   INCLM: 514/423.000
       INCLS: 514/561.000; 514/460.000
NCL    NCLM:  514/423.000
       NCLS:  514/460.000; 514/561.000
IC     IPCI   A61K0031-401 [I,A]; A61K0031-198 [I,A]; A61K0031-185 [I,C*];
              A61K0031-366 [I,A]
       IPCR   A61K0031-401 [I,A]; A61K0031-185 [I,C]; A61K0031-198 [I,A];
              A61K0031-366 [I,C]; A61K0031-366 [I,A]; A61K0031-401 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 20 OF 29  USPATFULL on STN
Full Text
AN     2005:313191  USPATFULL
TI     Compositions comprising nebivolol
IN     Davis, Eric, Morgantown, WV, UNITED STATES
       O'Donnell, John, Morgantown, WV, UNITED STATES
       Bottini, Peter, Morgantown, WV, UNITED STATES
PI     US 2005272810       A1  20051208
AI     US 2005-141235      A1  20050531 (11)
PRAI   US 2004-577423P     20040604 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1960
INCL   INCLM: 514/456.000
NCL    NCLM:  514/456.000
IC     [7]
       ICM    A61K031-353
       IPCI   A61K0031-353 [ICM,7]; A61K0031-352 [ICM,7,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 21 OF 29  USPATFULL on STN
Full Text
AN     2005:57279  USPATFULL
TI     Indirect delivery of growth factors into the central nervous system
IN     Hutchinson, Michael, New York, NY, UNITED STATES
```

```
       Gianutsos, John, New York, NY, UNITED STATES
PI     US 2005049196        A1  20050303
AI     US 2004-927301       A1  20040826 (10)
PRAI   US 2003-499232P      20030829 (60)
DT     Utility
FS     APPLICATION
LN.CNT 787
INCL   INCLM: 514/012.000
NCL    NCLM:  514/012.000
IC     [7]
       ICM    A61K038-18
       IPCI   A61K0038-18 [ICM,7]
       IPCR   A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0038-18 [I,C*];
              A61K0038-18 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 22 OF 29  USPATFULL on STN
Full Text
AN     2005:31556  USPATFULL
TI     Uses of ion channel modulating compounds
IN     Beatch, Gregory N., Vancouver, CANADA
       Ezrin, Alan M., Miami, FL, UNITED STATES
PI     US 2005026993        A1  20050203
AI     US 2004-838470       A1  20040503 (10)
PRAI   US 2003-467159P      20030502 (60)
       US 2003-493392P      20030807 (60)
       US 2003-516248P      20031031 (60)
       US 2003-516486P      20031031 (60)
       US 2003-526911P      20031203 (60)
       US 2003-527169P      20031204 (60)
       US 2003-528251P      20031208 (60)
       US 2004-544941P      20040213 (60)
       US 2004-559405P      20040401 (60)
DT     Utility
FS     APPLICATION
LN.CNT 5687
INCL   INCLM: 514/424.000
NCL    NCLM:  514/424.000
IC     [7]
       ICM    A61K031-4015
       IPCI   A61K0031-4015 [ICM,7]
       IPCR   A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61K0031-455 [I,C*];
              A61K0031-455 [I,A]; A61K0031-4965 [I,C*]; A61K0031-4965 [I,A];
              A61K0031-519 [I,C*]; A61K0031-519 [I,A]; C07D0207-00 [I,C*];
              C07D0207-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 23 OF 29  USPATFULL on STN
Full Text
AN     2003:334686  USPATFULL
TI     Vascularized organized tissues and uses thereof
IN     Vandenburgh, Herman H., Providence, RI, UNITED STATES
       Valentini, Robert F., Cranston, RI, UNITED STATES
       Wang, Xiao, Providence, RI, UNITED STATES
       Shansky, Janet, Barrington, RI, UNITED STATES
       Ferland, Paulette, Tiverton, RI, UNITED STATES
       DelTatto, Michael, Bristol, RI, UNITED STATES
PA     Cell Based Delivery Inc. (U.S. corporation)
PI     US 2003235561        A1  20031225
AI     US 2002-281765       A1  20021028 (10)
PRAI   US 2002-391330P      20020625 (60)
       US 2002-399605P      20020730 (60)
DT     Utility
FS     APPLICATION
LN.CNT 5322
INCL   INCLM: 424/093.210
       INCLS: 435/455.000; 435/366.000
NCL    NCLM:  424/093.210
       NCLS:  435/366.000; 435/455.000
IC     [7]
       ICM    A61K048-00
       ICS    C12N005-08; C12N015-85
```

IPCI A61K0048-00 [ICM,7]; C12N0005-08 [ICS,7]; C12N0015-85 [ICS,7]
IPCR A61K0035-12 [N,C*]; A61K0035-12 [N,A]; A61K0048-00 [I,C*];
A61K0048-00 [I,A]; C12N0005-00 [I,C*]; C12N0005-00 [I,A];
C12N0005-06 [I,C*]; C12N0005-06 [I,A]; C12N0005-08 [I,C*];
C12N0005-08 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 24 OF 29 USPATFULL on STN
Full Text
AN 2003:325140 USPATFULL
TI Use of methylphenidate compounds to enhance memory
IN Wiig, Kjesten A., Providence, RI, UNITED STATES
Epstein, Mel H., Bristol, RI, UNITED STATES
PA Sention, Inc., Providence, RI (U.S. corporation)
PI US 2003229122 A1 20031211
AI US 2003-374732 A1 20030225 (10)
RLI Continuation of Ser. No. WO 2001-US26829, filed on 28 Aug 2001, PENDING
PRAI US 2000-228525P 20000828 (60)
US 2000-235971P 20000928 (60)
US 2000-248278P 20001114 (60)
DT Utility
FS APPLICATION
LN.CNT 2329
INCL INCLM: 514/317.000
INCLS: 424/449.000; 514/432.000; 514/459.000
NCL NCLM: 514/317.000
NCLS: 424/449.000; 514/432.000; 514/459.000
IC [7]
ICM A61K031-445
ICS A61K031-382; A61K031-35; A61K009-70
IPCI A61K0031-445 [ICM,7]; A61K0031-382 [ICS,7]; A61K0031-35 [ICS,7];
A61K0009-70 [ICS,7]
IPCR A61K0031-35 [I,C*]; A61K0031-35 [I,A]; A61K0031-382 [I,C*];
A61K0031-382 [I,A]; A61K0031-445 [I,C*]; A61K0031-445 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 25 OF 29 USPATFULL on STN
Full Text
AN 2003:257302 USPATFULL
TI Solid carriers for improved delivery of active ingredients in
pharmaceutical compositions
IN Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
PI US 2003180352 A1 20030925
AI US 2002-159601 A1 20020530 (10)
RLI Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001,
PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999,
GRANTED, Pat. No. US 6248363
DT Utility
FS APPLICATION
LN.CNT 4625
INCL INCLM: 424/465.000
INCLS: 514/338.000
NCL NCLM: 424/465.000
NCLS: 514/338.000
IC [7]
ICM A61K031-4439
ICS A61K009-20
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0009-20
[ICS,7]
IPCR A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-22 [I,C*];
A61K0009-22 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A];
A61K0009-50 [N,C*]; A61K0009-50 [N,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 26 OF 29 USPATFULL on STN
Full Text
AN 2003:152382 USPATFULL
TI Pharmaceutical dosage forms for highly hydrophilic materials
IN Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Krill, Steven L., Danbury, CT, UNITED STATES

Venkateshvaran, Srinivasan, Salt Lake City, UT, UNITED STATES
PA LIPOCINE, INC. (U.S. corporation)
PI US 2003104048 A1 20030605
AI US 2002-158206 A1 20020529 (10)
RLI Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, GRANTED, Pat. No. US 6451339 Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192 Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985
DT Utility
FS APPLICATION
LN.CNT 2976
INCL INCLM: 424/451.000
INCLS: 424/400.000
NCL NCLM: 424/451.000
NCLS: 424/400.000
IC [7]
ICM A61K009-00
ICS A61K009-48
IPCI A61K0009-00 [ICM,7]; A61K0009-48 [ICS,7]
IPCR A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0031-57 [I,C*]; A61K0031-57 [I,A]; A61K0038-12 [I,C*]; A61K0038-13 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 27 OF 29 USPATFULL on STN
Full Text
AN 2003:112567 USPATFULL
TI Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IN Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Venkateshwaran, Srinivasan, Salt Lake City, UT, UNITED STATES
Krill, Steven L., Park City, UT, UNITED STATES
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
PI US 2003077297 A1 20030424
AI US 2002-74687 A1 20020211 (10)
RLI Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, PENDING Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192 Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001, PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DT Utility
FS APPLICATION
LN.CNT 4845
INCL INCLM: 424/400.000
NCL NCLM: 424/400.000
IC [7]
ICM A61K009-00
IPCI A61K0009-00 [ICM,7]
IPCR A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-50 [N,C*]; A61K0009-50 [N,A]; A61K0031-57 [I,C*]; A61K0031-57 [I,A]; A61K0038-12 [I,C*]; A61K0038-13 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 28 OF 29 USPATFULL on STN
Full Text
AN 2002:243602 USPATFULL
TI Use of methylphenidate compounds to enhance memory
IN Epstein, Mel, Bristol, RI, UNITED STATES
Wiig, Kjesten A., Providence, RI, UNITED STATES
PI US 2002132793 A1 20020919
AI US 2002-87232 A1 20020228 (10)
RLI Continuation-in-part of Ser. No. US 2001-941238, filed on 28 Aug 2001, PENDING
PRAI US 2000-228478P 20000828 (60)
US 2000-235972P 20000928 (60)
DT Utility
FS APPLICATION

```
LN.CNT 3025
INCL    INCLM: 514/079.000
        INCLS: 514/317.000; 705/002.000
NCL     NCLM:  514/079.000
        NCLS:  514/317.000; 705/002.000
IC      [7]
        ICM    A61K031-675
        ICS    A61K031-445; G06F017-60
        IPCI   A61K0031-675 [ICM,7]; A61K0031-445 [ICS,7]; G06F0017-60 [ICS,7]
        IPCR   A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0031-4458 [I,C*];
               A61K0031-4458 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 29 OF 29  USPATFULL on STN
Full Text
AN      2002:192091  USPATFULL
TI      Use of threo-methylphenidate compounds to enhance memory
IN      Epstein, Mel, Bristol, RI, UNITED STATES
        Wiig, Kjesten A., Providence, RI, UNITED STATES
PI      US 2002103162       A1  20020801
AI      US 2001-941238      A1  20010828 (9)
PRAI    US 2000-228478P     20000828 (60)
        US 2000-235972P     20000928 (60)
DT      Utility
FS      APPLICATION
LN.CNT 2476
INCL    INCLM: 514/079.000
        INCLS: 514/183.000; 514/210.010; 514/315.000; 514/326.000; 514/408.000;
               514/430.000; 514/449.000
NCL     NCLM:  514/079.000
        NCLS:  514/183.000; 514/210.010; 514/315.000; 514/326.000; 514/408.000;
               514/430.000; 514/449.000
IC      [7]
        ICM    A61K031-675
        ICS    A61K031-445; A61K031-397; A61K031-40; A61K031-38
        IPCI   A61K0031-675 [ICM,7]; A61K0031-445 [ICS,7]; A61K0031-397 [ICS,7];
               A61K0031-40 [ICS,7]; A61K0031-38 [ICS,7]
        IPCR   A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0031-4458 [I,C*];
               A61K0031-4458 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l22 kwic 16

L22  ANSWER 16 OF 29  USPATFULL on STN
SUMM    . . . brain injury, brain aneurysm, stroke, schizophrenia, epilepsy,
        chronic fatigue syndrome, fibromyalgia syndrome, chemotherapy (e.g.,
        cancer chemotherapy), traumatic brain injury, and Parkinson's disease.
        Following exposure to a muscarinic cholinergic receptor antagonist, such
        as atropine or scopolamine, humans can experience impairment of
        cognitive. . .
SUMM    . . . age-associated memory impairment, minimal cognitive
        impairment, amnesia, dementia, learning disabilities, memory impairment
        associated with toxicant exposure, brain injury, brain aneurysm,
        Parkinson's disease, head trauma, Huntington's disease, Pick's
        disease, Creutzfeldt-Jakob disease, stroke, schizophrenia, epilepsy,
        Multiple Sclerosis, mental retardation, Alzheimer's disease, age,
        age-associated. . .
SUMM    . . . age-associated memory impairment, minimal cognitive
        impairment, amnesia, dementia, learning disabilities, memory impairment
        associated with toxicant exposure, brain injury, brain aneurysm,
        Parkinson's disease, head trauma, Huntington's disease, Pick's
        disease, Creutzfeldt-Jakob disease, stroke, schizophrenia, epilepsy,
        Multiple Sclerosis, mental retardation, Alzheimer's disease, age,
        attention. . . hyperactivity disorder, Anterior Communicating Artery
        Syndrome, age-associated memory impairment, Mild Cognitive Impairment,
        chronic fatigue syndrome, fibromyalgia, chemotherapy, traumatic brain
        injury, Parkinson's disease or AIDS-related dementia, which
        amphetamine compound is represented by Formula II:    ##STR7##
SUMM    . . . age-associated memory impairment, minimal cognitive
        impairment, amnesia, dementia, learning disabilities, memory impairment
        associated with toxicant exposure, brain injury, brain aneurysm,
```

Parkinson's disease, head trauma, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, stroke, schizophrenia, epilepsy, mental retardation, Alzheimer's disease, age, age-associated memory impairment,. . . disorder, attention deficit hyperactivity disorder, Multiple Sclerosis, Anterior Communicating Artery Syndrome chronic fatigue syndrome, fibromyalgia syndrome, chemotherapy, traumatic brain injury, **Parkinson**'s disease or AIDS-related dementia, which amphetamine compound is represented by Formula III: ##STR8##

SUMM . . . age-associated memory impairment, minimal cognitive impairment, amnesia, dementia, learning disabilities, memory impairment associated with toxicant exposure, brain injury, brain aneurysm, **Parkinson**'s disease, head trauma, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, stroke, schizophrenia, epilepsy, mental retardation, Alzheimer's disease, age, age-associated memory impairment,. . .

SUMM . . . age-associated memory impairment, minimal cognitive impairment, amnesia, dementia, learning disabilities, memory impairment associated with toxicant exposure, brain injury, brain aneurysm, **Parkinson**'s disease, head trauma, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, stroke, schizophrenia, epilepsy, mental retardation, Alzheimer's disease, age, age-associated memory impairment,. . .

SUMM . . . of administering an effective amount of an amphetamine to a human having an impairment in a cognitive function associated with **Parkinson**'s disease, wherein the amphetamine is administered as a component of a composition that includes amphetamine and, optionally, a methamphetamine, wherein. . .

SUMM . . . of administering an effective amount of a methamphetamine to a human having an impairment in a cognitive function associated with **Parkinson**'s disease, wherein the methamphetamine is administered as a component of a composition that includes methamphetamine and, optionally, an amphetamine wherein. . .

SUMM . . . memory impairment, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or more points in time selected from the group consisting of before, concomitantly with. . .

SUMM . . . cognitive impairment, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or more points in time selected from the group consisting of before, concomitantly with. . .

SUMM . . . memory impairment, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or more points in time selected from the group consisting of before, concomitantly with. . .

SUMM . . . memory impairment, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or more points in time selected from the group consisting of before, concomitantly with. . .

SUMM . . . for cognitive impairment, comprising administering to the human at least one member selected the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or more points in time selected from the group consisting of before, concomitantly with. . .

SUMM . . . for cognitive impairment, comprising administering to the human at least one member selected the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or more points in time selected from the group consisting of before, concomitantly with. . .

SUMM . . . a human, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or

more points in time selected from the group consisting of before, concomitantly with. . .

SUMM . . . a human, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil before, concomitantly with, or subsequent to a cognitive impairment that is a consequence of exposure of. . .

SUMM . . . a human, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil before, concomitantly with, or subsequent to a memory impairment is a consequence of exposure of the. . .

SUMM . . . a human, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil before, concomitantly with, or subsequent to a memory impairment is a consequence of exposure of the. . .

SUMM . . . impairment, Alzheimer's disease, multiple sclerosis, mental retardation, brain aneurysm, chronic fatigue syndrome, fibromyalgia syndrome, chemotherapy, traumatic brain injury, stroke or **Parkinson**'s disease.

SUMM . . . and heart rate. In addition, treatment with at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil can potentially prevent, halt, reverse, diminish, attenuate or minimize the initiation or progression of an impairment. . .

DETD . . . aneurysm, age-associated memory impairment, mild cognitive impairment, epilepsy, mental retardation in children, and dementia resulting from a disease, such as **Parkinson**'s disease, Alzheimer's disease, AIDS, head trauma, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, age-associated memory impairment, Mild Cognitive Impairment, Multiple Sclerosis, Anterior Communicating Artery Syndrome, chronic fatigue syndrome, fibromyalgia syndrome, chemotherapy, traumatic brain injury, stroke or **Parkinson**'s disease. In addition, the compounds of the invention may be useful in enhancing memory in normal individuals.

DETD . . . human having mild cognitive impairment, Alzheimer's disease, multiple sclerosis, chronic fatigue syndrome, fibromyalgia syndrome, chemotherapy, traumatic brain injury, stroke or **Parkinson**'s disease. In another embodiment, methods of the invention are employed to improve a cognitive function in a human having an. . .

DETD . . . Multiple Sclerosis, age-associated memory impairment, Mild Cognitive Impairment, mental retardation in children, and dementia resulting from a disease, such as **Parkinson**'s disease, Alzheimer's disease, AIDS, head trauma, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, Anterior Communicating Artery Syndrome, hypoxia, post cardiac surgery,. . .

DETD . . . present invention also relates to treatment with at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine (also referred to as STRATTERA® or tomoxetine) and modafinil (also referred to as PROVIGIL®) to improve cognitive and. . .

DETD . . . a human, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or more points in time selected from the group consisting of before, concomitantly with. . .

DETD The amphetamine (e.g., l-amphetamine, d-amphetamine, l-methamphetamine, d-methamphetamine or any combination thereof), threo-methylphenidate (e.g., **d-threo-methylphenidate**, l-threo-methylphenidate, or any combination therof), methylphenidate, atomoxetine and modofinil are referred to herein, with respect to the methods of treating. . .

DETD . . . used herein, refers to the administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at a time

(e.g., minutes, hours, days, weeks, months) preceding exposure of the individual to the. . . is used interchangeably with "before." For example, at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil can be administered hours (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. . .

DETD In another embodiment, at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil can be administered concomitantly (also referred to herein as "at about the same point in time". . .

DETD . . . to the simultaneous or sequential administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil to the human and exposure of the human to the muscarinic cholinergic receptor antagonist. Concomitant administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil and exposure to the muscarinic cholinergic receptor antagonist can occur by administering a single formulation, which contains both at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil; and the muscarinic cholinergic receptor antagonist, to the human. The single formulation results in simultaneous administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil; and exposure to the muscarinic cholinergic receptor antagonist.

DETD Additionally, or alternatively, at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil can be administered concomitantly to the human by sequential administration of a formulation of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil and a separate formulation of the muscarinic cholinergic receptor antagonist.

DETD Both the formulation of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil and the separate muscarinic cholinergic receptor antagonist formulation are concomitantly administered to the human by sequential. . . sequential administration can be the administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil followed by exposure to the muscarinic cholinergic receptor antagonist at about the same time; or exposure. . . receptor antagonist followed by the administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil to the human at about the same time.

DETD In yet another embodiment, at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil is administered subsequent to a memory and/or cognitive impairment that is a consequence of exposure of. . . used herein, refers to the administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil to the human after the human is exposed to the muscarinic cholinergic receptor antagonist. For example, at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil can be administered hours (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. . .

DETD Administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and

modafinil to the human before, concomitantly with and/or subsequent to a memory and/or cognition impairment that is. . .

DETD . . . memory impairment, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or more points in time selected from the group consisting of before, concomitantly with. . .

DETD . . . cognitive impairment, comprising administering to the human at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil at one or more points in time selected from the group consisting of before, concomitantly with. . .

DETD . . . or after treatment of the individual with at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil by one or more well established tests known to one of skill in the art. Such. . .

DETD . . . human before, during or after administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil is assessed or determined by a word recall test such as RAVLT.

DETD In a particular embodiment, at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil is administered to a human having an impairment in memory consolidation as a consequence of exposure. . .

DETD . . . reversed, prevented or reduced by treatment with at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil.

DETD The term "threo-methylphenidate," such as is used when referring to "l-threo-methylphenidate" and "**d-threo-methylphenidate**," means a compound represented by Formula XII, including its salts, acids, esters, amides, carbamates, Schiff bases, prodrugs and other structural. . .

DETD Racemic mixtures of **d-threo-methylphenidate** and l-threo-methylphenidate are referred to as d,l, (+,-), (±), or DL.

DETD . . . percent (w/w or mole percent) of one enantiomer relative to another enantiomer (e.g., l-amphetamine relative to d-amphetamine; or l-threo-methylphenidate to **d-threo-methylphenidate**). For example, an amphetamine compound employed in the methods of the invention can be l-amphetamine, wherein the l-amphetamine is administered. . .

DETD . . . and methylphenidate compounds employed are about 100 percent (w/w or mole percent) l-amphetamine relative to d-amphetamine; or l-threo-methylphenidate relative to **d-threo-methylphenidate** is about 100 percent (w/w or mole percent). An amphetamine or threo-methylphenidate compound that is "about 100 percent" l-amphetamine, l-methamphetamine. . . An amphetamine or threo-methylphenidate compound that is "about 100 percent" can have insignificant traces of other components, such as d-amphetamine, **d-threo-methylphenidate**.

DETD . . . in cognitive or memory processes after administering at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil to the human can be determined at one or more time points following administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil.

DETD . . . or cognition in the human before administering at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil to the improvement in memory in the human after administering the compound.

DETD . . . is assessed prior to administration of the at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil and determined after administration of at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-**

methylphenidate, methylphenidate, atomoxetine and modafinil by a word recall test such as RAVLT (Rey, A. (1941). L'examen psychologique dans les cas. . .

DETD . . .. impaired memory or impaired cognition is administered at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil to improve the impairment in memory and/or cognition.

DETD . . . the invention, the human can be administered at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil concomitantly with and/or subsequent to the memory and/or cognitive impairment that is a consequence of exposure. . . nerve gas exposure can be treated with at least one member selected from the group consisting of l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil, concomitantly with or subsequent to exposure of the human to the atropine to prevent, minimize, alleviate. . .

DETD . . . embodiment of the methods of the invention, the compound(s) employed in the methods of the invention (e.g., l-amphetamine, l-methamphetamine, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) is administered as a single oral dosage formulation of at least about 2.5 mg to about. . . about 75 mg, about 100 mg or about 125 mg of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) and a pharmaceutically acceptable carrier.

DETD . . . about 500 mg, about 750 mg, or about 1000 mg of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil).

DETD . . . another embodiment, the methods of the invention employ multiple doses of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil). Each dose of the multiple dose is at least about 0.001 mg, about 0.01 mg, about. . . about 500 mg, about 750 mg or about 1000 mg of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil). The multiple doses can be administered for a day, days, a week, weeks, a month, months. . .

DETD . . . acutely (briefly or short-term) or chronically (prolonged or long-term). For example, the compounds, (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) of the invention can be used in methods to treat a human by administering the compound. . .

DETD . . . 1 mg to about 1000 mg of the compound employed in the methods (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) and, optionally, a pharmaceutically acceptable carrier.

DETD . . . further embodiment, the methods of the invention employ multiple doses of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil), wherein each of the multiple doses of the compound is between about 0.001 mg to about. . . about 250 mg, about 500 mg or about 1000 mg of the compound(s) (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) and, optionally, a pharmaceutically acceptable carrier.

DETD . . . embodiment, the methods of the invention employ a single dose of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) between about 0.0015 mg/kg to about 2 mg/kg; or between about 0.015 mg/kg to about 2. . .

DETD . . . about 1.50 mg/kg, about 1.80 mg/kg or about 3.5 mg/kg of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**,

methylphenidate, atomoxetine and modafinil).

DETD . . . additional embodiment, the methods of the invention employ multiple doses of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil), wherein each dose of the multiple dose is between about 0.0015 mg/kg to about 2 mg/kg;. . .

DETD . . . about 1.50 mg/kg, about 1.80 mg/kg or about 3.5 mg/kg of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil).

DETD The cumulative dose of the compounds (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) employed in the methods of the invention, regardless of whether the compound is administered in a. . .

DETD . . . of the compound can be any combination of a compound of the invention (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) in any combination of dose or doses.

DETD . . . "effective amount" or "amount effective," when referring to the amount of the compound (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) administered to the individual, is defined as that amount, or dose, of the compound that, when. . .

DETD . . . of the present invention can be accomplished by the administration of the compounds (e.g., l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) of the invention by enteral or parenteral means. Specifically, the route of administration can be by. . .

DETD . . . meant to include simultaneous or sequential administration of one or more of the compounds (l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil) individually or in combination. The simultaneous or sequential administration of compounds of the invention is conducted. . . multiple routes of administration (e.g., oral, transdermal, suppository, intramuscular) can be used to administer l-amphetamine, C105, l-methamphetamine, SN522, SN522-HCl, l-threo-methylphenidate, **d-threo-methylphenidate**, methylphenidate, atomoxetine and modafinil or any combination thereof.

DETD . . . drugs, or anatomical lesions (dementia), associated with multiple sclerosis, chronic fatigue syndrome, fibromyalgia syndrome, chemotherapy, traumatic brain injury, stroke or **Parkinson**'s disease. Indications for which such preparations may be useful include learning disabilities, memory impairment, e.g., due to toxicant exposure, brain. . .

DETD . . . is fulfilled:

1. Subjects who had memory deficits caused by concomitant medication usage or other significant neurological/psychological disease, e.g., **Parkinson**'s Disease, stroke, TIA, Multi-Infarct Dementia, Huntington's Disease, head trauma, or chronic CNS infection.
2. Evidence of other medical causes. . .

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	68.85	140.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.92

STN INTERNATIONAL LOGOFF AT 18:17:22 ON 07 JUN 2007